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Irritable bowel syndrome (IBS) is a common gastrointestinal (GI) disorder that 
affects an estimated 1 in 10 people globally (Black & Ford, 2020). Since IBS is such a 
common GI disorder worldwide it is important to understand that impact it has on quality 
of life. This study assessed the differences in the effects of IBS on the quality of life in 
patients with each of the three types of IBS: IBS-D, IBS-C, and IBS-M. Potential 
respondents were recruited via social media using an online survey, which collected 
demographics and assessed the effects of IBS on quality of life. The survey was also 
emailed to FODMAP trained dietitians who were asked to share the survey with their 
patients. Data collection lasted for approximately 9 weeks. One hundred and ninety-two 
responses were analyzed. Descriptive statistics for demographic data were reported as 
frequencies and correlated to the quality of life subscale scores. An ANOVA was used to 
analyze the differences between the total quality of life scores and subscale scores among 
patients with IBS-D, IBS-C, and IBS-M. An ANOVA was also used to analyze the 
differences between total quality of life scores among the different races, education 
levels, and monthly spending on IBS. A t-test was used to analyze the differences 
between quality of life subscale scores among female and male patients. A p-value ≤ 0.05 
indicated significance. A significant difference in total quality of life scores was found 
between groups based on how much money participants spend monthly on treatments 





were found in quality of life subscales scores among IBS-M, IBS-C, and IBS-D 
patients in the interference with activities (F(3, 178)= 5.83, p= 0.001), body image (F(3, 
185)= 3.61, p= 0.014), and health worry subscales (F(3, 183)= 4.83, p= 0.003). 
Significant differences were also found in quality of life subscale scores among white, 
non-Hispanic; whites, Hispanic origin; and others (Native Americans, Asian/Pacific 
Islanders, multi-racial, and Asian Indians) in the dysphoria (F(2, 181)= 3.86, p= 0.23), 
social reaction (F(2, 182)= 3.23, p= 0.42), and relationships subscales (F(2, 184)= 3.58, 
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CHAPTER 1  
INTRODUCTION 
 Irritable bowel syndrome (IBS) is one of the most commonly diagnosed 
functional bowel disorders, affecting an estimated 1 in 10 people globally (Black & Ford, 
2020). IBS is defined as abdominal pain or discomfort associated with at least 2 of the 
following symptom groups: symptoms associated with changes in frequency of 
defecation, symptom relief associated with defecation, and symptoms associated with 
changes in consistency of stool (Bohn et al., 2015; Endo, Shoji, & Fukudo, 2015; Simren, 
Palsson, & Whitehead, 2017). Symptoms associated with IBS include chronic bloating, 
gas, diarrhea, abdominal distention, constipation, and nausea (National Institute of 
Diabetes and Digestive and Kidney Diseases, 2017). IBS seems to have a significant 
impact on the health-related quality of life of the patients who suffer from the syndrome 
(El-Salhy, 2012; Jamali et al., 2012; Singh et al., 2015).  
    Statement of the Problem 
 Irritable bowel syndrome has been found to negatively impact the quality of life 
of the patients who suffer from it (Agarwal & Spiegel, 2011; Cho et al., 2011; Jamali et 
al., 2012; Jerndal et al., 2010; Kopczyńska, Mokros, Pietras, & Małecka-Panas, 2018; 
Østgaard, Hausken, Gundersen, & El-Salhy, 2012; Wang et al., 2012). IBS-diarrhea 
(IBS-D) negatively impacts the quality of life of patients (Andrae, Patrick, Drossman, & 




of IBS-Constipation (IBS-C) and IBS-Mixed (IBS-M) specifically on quality of life has 
been conducted. One study comparing the quality of life in IBS-D patients versus IBS-C 
patients found that quality of life scores tend to be lower in patients with IBS-D than IBS-
C (Singh et al., 2015). Additional research is necessary to examine the differences among 
quality of life in patients with IBS-D, IBS-C, and IBS-M.  
Purpose 
 The purpose of this study was to examine the differences in the effects of IBS on 
the quality of life in patients with each of the three types of IBS: IBS-D, IBS-C, and IBS-
M. The IBS-Quality of Life (IBS-QOL) questionnaire assesses quality of life using eight 
subscales: body image, dysphoria, interference with activities, healthy worry, food 
avoidance, social reactions, sexual health, and effect on relationships (Singh et al., 2015). 
This study also examined the quality of life score differences between genders, races, 
education levels, and monthly spending on IBS categories of patients with IBS-D, IBS-C, 
and IBS-M.  
Hypotheses  
The following hypotheses were tested: 
1. There will be no significant difference in the quality of life scores among patients 
with IBS-D, IBS-C, and IBS-M.  
2. There will be no significant difference in the quality of life scores between 
genders in patients with IBS-D, IBS-C, and IBS-M.  
3. There will be no significant difference in the quality of life sub scores among 






Approximately 10-20% of the global population is diagnosed with IBS with only 
12% of those patients seeking healthcare or treatment for their IBS symptoms (Black & 
Ford, 2020; Saha, 2014). IBS is a frustrating condition for many patients due to the lack 
of effective treatment plans and the lack of visible signs of disease or damage in the 
digestive tract (Betram et al., 2001; National Institute of Diabetes and Digestive and 
Kidney Diseases, 2017). According to Al Huthail (2013), many IBS patients feel 
dissatisfied with their perceived physician-patient relationship due to a feeling of being 
insufficiently educated about their condition and a lack of an adequate explanation for 
their symptoms. IBS patients also often feel that their concerns are not taken seriously by 
their physician and many report perceived uncaring attitudes from medical professionals 
(Bertram et al., 2001; Bjorkman, Simren, Ringstrom, & Ung, 2016; Hakanson et al., 
2010). Due to this, many IBS patients fail to seek medical care because they feel a 
consultation with a physician will provide little help (Al Huthail, 2013). If more research 
is conducted investigating the quality of life of patients with IBS it is possible that 
physicians may approach these patients differently. More research about the quality of 
life in IBS patients may help physicians understand how much IBS impacts the life of 
patients, so they may be more understanding and willing to find ways to improve 
symptoms. There is limited research regarding the quality of life in patients with IBS-C 
and IBS-M, so this study is needed to provide additional data to the current body of 








REVIEW OF LITERATURE 
 Irritable bowel syndrome (IBS) is a common gastrointestinal (GI) disorder that 
affects an estimated 1 in 10 people globally (Black & Ford, 2020). The exact 
pathophysiology of IBS is unclear, but IBS is defined as a group of symptoms that occur 
together without any visible signs of disease or damage in the digestive tract (National 
Institute of Diabetes and Digestive and Kidney Diseases, 2017). Despite the lack of 
physical damage in the digestive tract, IBS can significantly reduce quality of life with 
the same degree of impairment as major chronic diseases, like diabetes, congestive heart 
failure, kidney disease, and hepatic cirrhosis (El-Salhy, 2012). Quality of life with IBS 
has been found to be affected by psychiatric symptoms, GI symptoms, disease severity, 
and gender (Singh et al., 2015). The symptoms that commonly occur in IBS may include 
chronic abdominal pain, diarrhea, constipation, changes in bowel movements, abdominal 
distension, bloating, and gas. Symptoms and the severity of symptoms can vary 
drastically between patients (National Institute of Diabetes and Digestive and Kidney 
Diseases, 2017). It is estimated that 41% of patients have mild IBS, 35% of patients have 
moderate IBS, and 25% of patients are considered to have severe IBS (Corsetti & 
Whorwell, 2017). Mild IBS is considered to include 1-3 symptoms, mild/intermittent 




 days per year), health care utilization 0-1 time per year, and lack of or mild 
psychological distress (Drossman et al., 2011). Moderate IBS is considered to include 4-6 
symptoms, including moderate and frequent abdominal pain, fair health-related quality of 
life, 15-50 days of activity restriction per year, moderate psychological distress, and 
health care utilization 2-4 times per year. Severe IBS is considered to include 7 or more 
symptoms, poor health-related quality of life, >50 days of activity restriction per year, 
severe psychological distress, severe and constant abdominal pain, and health care 
utilization 5 or more times per year (Drossman et al., 2011). Frequency of symptoms can 
also vary among patients. Some patients may experience symptoms daily, while other 
patients may experience symptoms at intervals of weeks or months at a time (El-Salhy, 
2012). IBS can be difficult to diagnose due to the lack of visible damage within the 
digestive tract. Typically, IBS is diagnosed by eliminating other GI disorders such as: 
ulcerative colitis, crohn’s disease, diverticulitis, small intestinal bacterial overgrowth 
(SIBO), celiac disease, non-celiac gluten sensitivity, and lactose intolerance (Borghini, 
Donato, Alvaro, & Picarelli, 2017).   
Prevalence of Irritable Bowel Syndrome 
Approximately 12% of IBS patients seek healthcare related to the treatment of 
IBS (Saha, 2014).  According to the World Gastroenterology Organization approximately 
1/3 of IBS patients have IBS-diarrhea (IBS-D), 1/3 of patients have IBS-constipation 
(IBS-C), and 1/3 of patients have IBS-mixed with diarrhea and constipation (IBS-M) 
(Corsetti & Whorwell, 2017). In the United States, IBS affects approximately 15% of the 
population, but many patients do not seek health care for their condition (Qureshi et al., 




prescriptions. IBS is the most common diagnosis made by gastroenterologists in the 
United States (Qureshi et al., 2016).  In Western countries IBS tends to be more common 
in women, while in Eastern countries IBS is not found to be more common in women 
than men. It has been hypothesized that IBS is under diagnosed in Asia and other Eastern 
countries (Saha 2014). Approximately 6.5%-10.1% of the Asian population meets the 
criteria for IBS (Chang, Lu, & Chen, 2010). Lovell and Ford (2012) collected data from 
studies conducted in Northern Europe and Southeast Asia. This meta-analysis found that 
IBS occurs more commonly in women than men and age was not a factor in diagnosis 
(Lovell & Ford, 2012). These results are different than results found by Pan, Chang, Su, 
and Tsai (2016), who found that the incidence of IBS significantly increased with age.  
Anbardan et al. (2012) conducted a study examining gender in a sample of 144 
patients with IBS in Tehran, Iran. These researchers found that 69.4% of the patients with 
IBS were female and 30.6% of the patients were male. These results align with the results 
from the meta-analysis conducted by Lovell and Ford (2012) and the study conducted by 
Pan, Chang, Su, and Tsai (2016) which found that IBS is more common in women than 
men. IBS-D was more common in men (38.6%), while IBS-C was more common in 
women (38%). Kosako, Akiho, Miwa, Kanazawa, and Fukudo (2018) conducted an 
internet survey of 30,000 Japanese IBS-C patients and abdominal discomfort, abdominal 
distention, and abdominal fullness were significantly more common in female subjects 
than male subjects. Abdominal distention and abdominal pain were also significantly 
more common in IBS-C patients aged 20-49 years than those aged 50-79 years (Kosako, 
Akiho, Miwa, Kanazawa, & Fukudo, 2018). Between 1995-2005, IBS was diagnosed in 




patients 74% were female and the mean age at time of diagnosis was 46 years. Internists 
made 68% of diagnoses, gastroenterologists made 13% of diagnoses, and others made 
19% of diagnoses (Ladabaum et al., 2011).  
Diagnosis of Irritable Bowel Syndrome 
A variety of methods can be used to diagnose IBS including reviewing the 
patient’s symptoms, reviewing the patient’s medical history, evaluating the patient for 
warning signs of more severe conditions, performing a physical examination, and using 
the Rome IV Criteria (Lacy & Patel, 2017). The presence of additional functional GI 
disorders and extraintestinal disorders such as, fibromyalgia, migraines, gastroesophageal 
reflux disease (GERD), dyspepsia, and interstitial cystitis, may increase the likelihood of 
a positive IBS diagnosis (Lacy, 2016). Warning signs for more severe conditions include 
anemia, hematochezia, unintentional weight loss, and family history of colorectal cancer 
or inflammatory bowel diseases. The Rome IV Criteria were developed by an 
international panel of experts in the field of functional GI disorders. The Rome IV 
Criteria define IBS as a functional bowel disorder with chronic abdominal pain that is 
associated with a change in bowel habits. Diarrhea, constipation, or a mix of diarrhea and 
constipation are disordered bowel habits. The Rome IV Criteria are chronic abdominal 
pain at least 1 day per week over the last 3 months, associated with two or more of the 
following criteria: related to defecation, associated with a change in stool frequency, or 
associated with a change in appearance or form of stool (Endo, Shoji, & Fukudo, 2015; 
Simren, Palsson, & Whitehead, 2017). These criteria must be met over the previous 3 
months and symptom onset must have occurred at least 6 months prior to diagnosis 




IBS and they are characterized by abdominal pain which improves with defecation and 
whose onset is associated with a change in frequency or form of stool and is not 
attributed to structural or biochemical abnormalities (Sandhu & Paul, 2014).  
Irritable Bowel Syndrome-Constipation (IBS-C) 
IBS can be divided into three different types based on the predominant change in 
bowel habits: IBS-constipation (IBS-C), IBS-diarrhea (IBS-D), and IBS-mixed (IBS-M) 
(Mearin et al., 2016).  IBS-C can be compared to chronic constipation because both are 
functional bowel disorders. In IBS-C constipation, abdominal bloating, and abdominal 
distention are the predominant symptoms. IBS-C and chronic constipation are 
characterized by visceral hypersensitivity and abnormalities in gut motility (Nellesen, 
Yee, Chawla, Lewis, & Carson, 2013). IBS-C is characterized by abdominal discomfort 
or pain with disturbed defecation, while chronic constipation is simply characterized by 
sporadic and infrequent bowel movements, hard stools, straining, and feeling of 
incomplete bowel evacuation. Functional or chronic constipation (with or without IBS) 
can be classified according to the pathophysiological mechanism associated with the 
constipation including, functional defecatory disorders, slow colonic transit time, and 
normal colonic transit time. Approximately 5.2%-66% of IBS patients are considered to 
have IBS-C (Nellesen, et al., 2013). DiBonaventura, Sun, Bolge, Wagner, and Mody 
(2011) used data from the 2007 National Health and Wellness Survey to assess the effects 
of IBS-C on health-related quality of life on patients lives. IBS-C was associated with 
reduced health-related quality of life, increased work productivity loss, increased activity 




significantly more doctors’ appointments and emergency room visits when compared to 
patients without IBS-C (DiBonaventura, Sun, Bolge, Wagner, & Mody, 2011).  
Irritable Bowel Syndrome-Diarrhea (IBS-D)  
 IBS-D is characterized by abdominal pain, loose or watery stools, abdominal 
bloating, and abdominal cramping (Buono, Carson, & Flores, 2017). Patients with IBS-D 
may also experience abdominal pain associated with frequent loose stools, a feeling of 
urgency not relieved by defecation, and mucus in the stool (Lacy, 2016). IBS-D 
symptoms can be infrequent and mild, moderate and occasionally bothersome, or severe 
enough to reduce the ability to have normal daily functioning (Lacy, 2016). 
Approximately 0.8%-33.98% of IBS patients are considered to have IBS-D (Nellesen, 
Yee, Chawla, Lewis, & Carson, 2013). The pathophysiology of IBS-D is not exactly 
known, but dietary factors, accelerated transit through the gastrointestinal tract, visceral 
hypersensitivity, and abnormalities in the gut microbiota may contribute to the 
development of IBS-D (Lacy, 2016).  Buono, Carson, and Flores (2017) examined the 
impact of IBS-D on health-related quality of life, work productivity, and daily activities, 
and found that IBS-D patients reported lower health-related quality of life compared to 
patients with asthma, gastroesophageal reflux disease (GERD), or migraines. These 
patients also reported more bodily pain, impaired social functioning, and worse mental 
health compared to patients with other chronic diseases (Buono, Carson, & Flores 2017). 
Singh et al. (2015), conducted a study examining the effect of IBS subtype on IBS-
specific quality of life using the Irritable Bowel Syndrome-Quality of Life (IBS-QOL) 
questionnaire. Of the 243 IBS patients included in the study 22.2% had IBS-C, 23.1% 




QOL and have increased food avoidance, effect on daily activities, and social relationship 
problems (Singh et al., 2015).  
Irritable Bowel Syndrome-Mixed (IBS-M) 
 IBS-M is characterized by varying GI symptoms including both diarrhea and 
constipation (Su, Shih, Presson, & Chang, 2013). The most common symptoms 
associated with IBS-M include irregular bowel habits, bloating, and abdominal pain. 
Nausea has also been found to be significantly more common in patients with IBS-M 
than patients with IBS-D or IBS-C. Irregular bowel habits can be defined as less than 3 
bowel movements per week or greater than 3 bowel movements per day (Su, Shih, 
Presson, & Chang, 2013).  
Quality of Life with Irritable Bowel Syndrome 
Many studies have found that IBS negatively impacts the quality of life of patient 
who experience symptoms (Buono, Carson, & Flores, 2017; DiBonaventura, Sun, Bolge, 
Wagner, & Mody, 2011; El-Salhy, 2012; and Singh et al., 2015). Symptom severity, 
anxiety, and depression have been associated with the overall IBS-QOL life score (Cho et 
al., 2011). Fear of GI symptoms has also been found to impact health-related quality of 
life in IBS patients (Lackner, Gudleski, Ma, Dewanwala, & Naliboff, 2014). Patients with 
worse bowel symptoms that occur more frequently have been found to have a lower 
health-related quality of life when compared to patients with mild, less frequent 
symptoms (Cho et al., 2011).  Singh et al. (2015), found that patients with IBS-D and 
IBS-M have significantly lower IBS-QOL scores than patients with IBS-C. IBS-D and 




avoidance when compared to patients with IBS-C which impacted the overall IBS-QOL 
score (Singh et al., 2015). IBS can significantly reduce quality of life with the same 
degree of impairment as major chronic diseases, like diabetes, congestive heart failure, 
kidney disease, and hepatic cirrhosis (El-Salhy, 2012). 
Economic Impact of Irritable Bowel Syndrome 
Due to the high prevalence of IBS in the United States and an increased demand 
of health care related to the condition, approximately $8 billion are spent on the medical 
costs of IBS patients per year (Qureshi et al., 2016). It is also estimated that an additional 
$25 billion are wasted by IBS patients who have undergone unnecessary procedures such 
as: appendectomies, hysterectomies, cholecystectomies, and other surgical procedures 
due to the difficulty associated with diagnosing IBS (Qureshi et al., 2016). According to 
Ladabaum et al. (2011), endoscopic and radiologic testing were most commonly used by 
gastroenterologists prior to being diagnosed with IBS. Canavan and Card (2014) found 
that 15%-43% of patients diagnosed with IBS pay out of pocket for treatments (such as 
medications) for their symptoms. Approximately 48% of patients with IBS incur some 
costs each year related to their IBS. International annual cost estimates per patient: $742-
$7,547 per year in the U.S.; $116–$409 per year in the UK; $670–$1,020 per year in 
France; $259 per year in Canada; $936 per year in Germany; $310 per year in Norway; 
and $92 per year in Iran (Canavan & Card, 2014). Doshi et al. (2014), conducted a 
retrospective analysis of health care costs associated with IBS in the United States and 
found that the mean health care costs for IBS patients was estimated to be $11,182 
annually. Over half of these costs were attributed to physician office visits and other 




(21.8%), prescriptions (19.1%), and ER visits (5.4%). Specific GI-related health care 
costs averaged $4,456 per year (approximately 39.8% of all-cause health care costs) 
(Doshi et al., 2014). Corsetti & Whorwell (2017) facilitated a report with a 
pharmaceutical company that states the major cause for the economic burden placed by 
IBS on health care services and society is the less than ideal management of the 
condition.  
A majority (90%) of consultations related to IBS are with a general practitioner 
and patients often repeatedly consult their general practitioner for management of IBS 
before being referred to a specialist (Corsetti & Whorwell, 2017). These primary care 
visits are estimated to account for 30% of total direct healthcare costs for IBS patients, 
while 25-30% of costs are attributed to inpatient healthcare. In the UK and US, patients 
diagnosed with IBS take an average of 8.5-21.6 days off work each year (Corsetti & 
Whorwell, 2017). According to a survey conducted by the American Gastroenterological 
Association, patients with IBS reported that their GI symptoms interfered with work 
productivity an average of 9 workdays per month and that they had to miss an average of 
2 days of work per month due to IBS symptoms (Buono, Carson, & Flores, 2017). 
Productivity loss due to IBS amounts to an annual loss of $748 per patient in Canada, 
$335 per patient in the U.S., $335 per patient in the UK, and $812 per patient in Iran 
(Corsetti & Whorwell, 2017). Despite the significant impact on quality life caused by 
IBS, it has been reported that only 60% of employers recognize IBS as a valid reason for 
absence from work (Corsetti & Whorwell, 2017). According to the Irritable Bowel 
Syndrome with Constipation (IBIS-C) study conducted in the UK, France, Germany, 




general practitioner, 100% consulted a gastroenterologist, and 24% of patients required 
an emergency department visit or inpatient hospital stay (Yiannakou et al., 2015).  
Additionally, 52% of patients required some type of diagnostic test, 90% took 
prescription drugs for IBS-C, 51% took sick leave due to their IBS symptoms, and 82% 
of patients incurred productivity losses (Yiannakou et al., 2015).  
Triggers for Irritable Bowel Syndrome Symptoms 
 Irritable bowel syndrome symptoms can vary among patients and the factors that 
trigger symptoms also vary widely (Qin, Cheng, Tang, & Bian, 2014; Saha, 2014; Volta 
et al., 2016). Triggers for IBS symptoms may include food triggers, lifestyle triggers, or 
internal causes. Some patients may experience symptoms caused by only specific triggers 
or combinations of a variety of different triggers (Qin, Cheng, Tang, & Bian, 2014; Saha, 
2014; Volta et al., 2016). 
Food Triggers 
 Approximately 60% of IBS patients relate the occurrence of their symptoms with 
the consumption of certain foods and many of these patients report worsening of 
symptoms within 15 minutes to a few hours after eating a meal (Volta et al., 2016). 
Monsbakken, Vandik, and Farup (2006) evaluated perceived food intolerances in IBS 
patients and found that 62% of participants limited or excluded certain foods from their 
diet and 12% were considered to have a nutritionally inadequate diet. El-Salhy et al. 
(2012), reported that the average diet of an IBS patient was low in calcium, magnesium, 
phosphorus, riboflavin, and vitamin A. Food related symptoms in IBS patients are 




evidence of an allergic reaction mediated by immunoglobulin E in response to foods in 
IBS.  
 Non-celiac gluten sensitivity (NCGS) is defined as having gastrointestinal and 
extra-intestinal symptoms, without celiac disease or a wheat allergy, but symptoms are 
improved by following a gluten-free diet (Volta et al., 2016). NCGS is characterized by 
symptoms such as: diarrhea, abdominal pain, bloating, gas, headache, fatigue, attention-
deficit/hyperactivity disorder, skin issues, or recurrent oral ulceration (Makharia, Catassi, 
& Makharia, 2015). Disorders related to gluten sensitivity or intolerance are recognized 
as commonly mimicking the symptoms of IBS (Makharia, Catassi, & Makharia, 2015). 
Physicians may perform celiac-specific serological tests in patients with suspected gluten 
sensitivity and if these tests are negative patients may be instructed to participate in a trial 
of a gluten/wheat free diet. If symptoms improve while the patient is on the gluten/wheat 
free diet a diagnosis of NCGS may be supported (Makharia, Catassi, & Makharia, 2015). 
In a double-blind randomized placebo-controlled study evaluating the effects of 
following a gluten free diet on symptoms in IBS patients, statistically significant 
differences, were found in overall symptoms among the gluten-containing group and 
placebo group (Shahbazkhani et al., 2015). Based on these results, the researchers 
concluded that many IBS patients may be sensitive to gluten (Shahbazkhani et al., 2015). 
A controlled-trial of a gluten-free diet in patients with IBS-D which found that 
participants consuming the gluten-containing diet had more bowel movements per day 
than the group following the gluten free diet (Vazquez-Roque et al., 2013). Despite 




participants in the gluten free diet group did not experience a significant difference in 
stool form (Vazquez-Roque et al., 2013).  
 Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols 
(FODMAP) are another category of foods that have been associated with the onset of IBS 
symptoms (Barret & Gibson, 2012). FODMAPs are defined as short-chain carbohydrates 
that are not completely absorbed in the GI tract (de Roest et al., 2013). These 
carbohydrates are also highly fermentable, so this increases the osmotic load in the 
intestines. Increased delivery of water to the colon and increased gas production in the 
colon causes luminal distention. This luminal distention leads to symptoms such as 
altered GI motility, bloating, abdominal pain/discomfort, and gas (de Roest et al., 2013). 
Many fruits, vegetables, and grains typically deemed healthy foods that should be 
included in the diet are FODMAPs. Examples of FODMAPs are lactose, fructose, 
sorbitol, mannitol, fructo-oligosaccharides, and galacto-oligosaccharides (Varney et al., 
2017). Foods are classified as high FODMAP containing, moderate FODMAP 
containing, and low FODMAP containing. High FODMAP foods can potentially lead to 
the worst IBS symptoms, while low FODMAP foods are often considered to be less 
likely to cause symptoms. Despite these generalizations, food triggers vary widely for 
IBS patients (Barrett & Gibson, 2012). Oligosaccharides are found in foods such as: 
wheat and rye products, nuts, legumes, onion, garlic, and artichokes. There is no an 
enzyme in the human body capable of completely breaking down fructans and galacto-
oligosaccharides, so they are malabsorbed. They are highly fermentable, so gas is 
produced causing bloating, abdominal pain, and excessive flatulence. Lactose is the 




cheeses. Fructose is the monosaccharide FODMAP and it is found in many foods 
including apples, pears, watermelon, mango, honey, sugar snap peas, and high fructose 
corn syrup. Fructose is highly osmotic and draws water into the lumen. This luminal 
distension can cause abdominal pain, bloating, diarrhea, and altered GI motility (Barrett, 
2017). Foods that contain polyols that might contribute to IBS symptoms include 
mushrooms, apples, pears, stone fruits, cauliflower, snow peas, and sugar-free chewing 
gum or mints. Polyols are slowly absorbed in the small intestine and can produce an 
osmotic effect similar to fructose (Barrett & Gibson, 2012).  
Lifestyle Triggers 
 Psychological and emotional stress are important factors in the development of 
IBS and can exacerbate the severity of symptoms (Qin, Cheng, Tang, & Bian, 2014). IBS 
is often described as a functional illness that is influenced by social, psychological, and 
physiological factors (Lackner et al., 2010). Psychological stresses have a significant 
impact on intestinal sensitivity, secretion, motility, and permeability. Approximately 94% 
of patients with IBS also have some type of psychiatric disorder or mental health issue 
such as depression or generalized anxiety disorder (Gulewitsch et al., 2013). Panic 
disorder is present in 25-44% of IBS patients, generalized anxiety disorder is present in 
32%, post-traumatic stress disorder is present in 36% of IBS patient, and major 
depressive disorder is present in 47% of IBS patients (Fadgyas-Stanculete, Buga, Popa-
Wagner, & Dumitrascu, 2014). Stress can induce alterations in the neuro-endocrine-
immune system pathway which act on the gut-brain axis and microbiota-gut-brain axis. 
These alterations can lead to exacerbation of IBS symptoms or symptom flare-ups (Qin, 




(CRF) can be stress-induced which may lead to disruptions in GI function. Immune 
system activation and low-grade inflammation also appear to be important in the 
development of IBS symptoms (O’Malley, Quigley, Dinan, & Cryan, 2011).  
 Stress and depression are related to IBS along with functional dyspepsia, and 
peptic ulcer disease (Lee et al., 2015). The incidence of IBS increased as stress levels 
increased (Lee et al., 2015). Mykletun et al. (2010), examined the prevalence of mood 
and anxiety disorders in IBS patients. The researchers found that 27.5% of patients with 
IBS also were currently suffering from a mood or anxiety disorder. Additionally, 50.5% 
of patients with lifetime IBS also reported having a lifetime psychiatric condition 
(Mykletun et al., 2010).  Kabra and Nadkarni (2013) found similar results when 
evaluating the prevalence of depression and anxiety in IBS patients. Kabra and Nadkarni 
(2013) found that 37.1% of participants had an anxiety disorder and 31.4% of participants 
suffered from depression.  They also found that IBS is significantly associated with low 
socio-economic status, lower education levels, and being single, divorced, or widowed 
(Kabra & Nadkarni, 2013). Gastrointestinal (GI) specific anxiety, which is anxiety related 
to GI symptoms and disorders, has been theorized to influence the quality of life and 
severity of symptoms in IBS patients (Gulewitsch et al., 2013; Jerndal et al., 2010).  
Jerndal et al. (2010), report that IBS patients have more severe GI specific anxiety when 
compared with healthy people. Severe GI specific anxiety is also associated with more 
severe GI symptoms, more severe generalized anxiety, lower socioeconomic status, and 






Potential Internal Causes for IBS Symptoms 
 Potential underlying causes of IBS may include minor inflammatory bowel 
disease, serotonin dysregulation, small intestine bacterial overgrowth, and central 
dysregulation (Saha, 2014).  Approximately 10% of IBS patients believe their IBS 
symptoms began after experiencing an infectious illness. Exposure to gastrointestinal 
infections can cause low-grade mucosal and systemic inflammation, which causes 
mucosal infiltration of immune cells, increased production of several cytokines, and an 
altered population of cells circulating through the bloodstream (Belmonte et al., 2012). 
Psychological stress has also been reported to be a factor that potentially induces immune 
activation (Ishihara et al., 2013). Serotonin dysregulation has been theorized to play a 
role in the onset of IBS (Saha, 2014). The 5-HT3 and 5-HT4 serotonin receptors play a 
significant role in controlling GI motility, sensation, and secretion (Spiller, 2001). 
Houghton et al. (2003), found that plasma 5-HT concentrations are elevated in IBS 
patients with diarrhea and reduced in IBS patients with constipation, especially in 
patients whose symptoms occur postprandially. Small intestinal bacterial overgrowth 
(SIBO) is seems to prevalent in IBS patients, but it remains unclear whether SIBO causes 
IBS (Spiegel, 2011). SIBO causes symptoms that mirror IBS symptoms such as: diarrhea, 
gas, bloating, constipation, nausea, abdominal pain, and fatigue. Moraru et al. (2014), 
found that 31.7% of IBS patients were diagnosed with SIBO. In this study SIBO was 
present in 45.7% of patients with IBS-D (Moraru et al., 2014). The central nervous 
system modulates gut secretions, motility, and blood flow, so central dysregulation may 





Potential Treatments for Irritable Bowel Syndrome 
 Due to the variety of triggers and causes for IBS symptoms there are also a wide 
variety of potential treatments that may be used to manage IBS (Halmos, Power, Sheperd, 
Gibson, & Muir, 2013; Hussain & Quigley, 2006; Kong et al., 2005; Khanna, 
MacDonald, & Levesque, 2014; Trinkley & Nahata, 2014). Potential treatments may 
include medications, peppermint oil, dietary changes, specific dietary patterns, probiotics, 
and other alternative treatments. Many patients go through a trial and error process to 
determine the treatment regimen that works the best to control their symptoms and 
effective treatment regimens often vary between patients (Halmos, Power, Sheperd, 
Gibson, & Muir, 2013; Hussain & Quigley, 2006; Kong et al., 2005; Khanna, 
MacDonald, & Levesque, 2014; Trinkley & Nahata, 2014).  
Medications 
 Currently there are no specific medications that are used as a first-line treatment 
for all patients with IBS (Trinkley & Nahata, 2014). Typically, when medications are 
prescribed for patients with IBS, the medication is chosen based on its efficacy for 
treating the patient’s specific symptoms. For example, a patient suffering from chronic 
diarrhea or IBS-D will require a different medication than a patient suffering from 
chronic constipation or IBS-C (Trinkley & Nahata, 2014). According to Trinkley and 
Nahata (2014) there is evidence that supports the improvement of certain IBS symptoms 
with many different medications including: loperamide, psyllium husk, lubiprostone, 
linaclotide, amitriptyline, trimipramine, desipramine, citalopram, fluoxetine, paroxetine, 
dicyclomine, rifaximin, ketotifen, pregabalin, gabapentin, and octreotide. These 




Citalopram, fluoxetine, and paroxetine are classified as selective serotonin reuptake 
inhibitors (SSRIs) and are typically used to treat anxiety and depression (Trinkley & 
Nahata, 2014). Amtitriptyline, desipramine, and trimipramine are tricyclic 
antidepressants that have been shown to improve IBS symptoms in some patients. 
Antispasmodics such as dicyclomine and hyoscyamine have also been used in the 
treatment of IBS (Trinkley & Nahata, 2014). Antispasmodics cause decreased GI motility 
and ease GI muscle spasms, which can improve abdominal pain and cramping in IBS 
patients (Roblin et al., 2009). Loperamide is the only antidiarrheal that has been found to 
be effective in patients with IBS-D. Loperamide works by inhibiting peristalsis, reducing 
stool frequency, and improving stool consistency (Roblin et al., 2009). LinzessTM is a 
medication that has been approved by the FDA for use in patients with IBS-C (Rao et al, 
2012). LinzessTM works by increasing the release of intestinal fluid, accelerating 
intestinal transit time, and reducing pain in the intestines, but LinzessTM also may cause 
diarrhea (Chey et al., 2012).   
Peppermint Oil 
 Peppermint oil naturally causes relaxation of the smooth muscles located 
throughout the gastrointestinal system, so it has been researched regarding its potential 
role in the treatment of IBS (Khanna, MacDonald, & Levesque, 2014). Peppermint oil 
also has several other mechanisms of action including visceral sensitivity modulation, 
anti-inflammatory activity, anti-microbial effects, and improvement of psychosocial 
stress (Chumpitazi, Kearns, & Shulman, 2018). Based on the meta-analysis performed by 
Khanna, MacDonald, and Levesque (2014) peppermint oil was found to cause a 




also been found to be beneficial in the treatment of functional dyspepsia, functional 
abdominal pain, and post-operative nausea (Chumpitazi, Kearns, & Shulman, 2018). 
Despite the potential positive effects of peppermint oil on IBS symptoms, heart burn has 
been identified as a potential negative side effect (Khanna, MacDonald, & Levesque, 
2014).  
Diets and Eating Patterns 
Many diets that have been theorized and tested in the management of IBS 
symptoms, but one of the most popular is the low FODMAP diet (Halmos, Power, 
Sheperd, Gibson, & Muir, 2013). The low FODMAP diet is an elimination diet that limits 
consumption of fermentable oligosaccharides, disaccharides, monosaccharides, and 
polyols (FODMAPs). Many of the foods that fall into these categories can trigger GI 
symptoms including gas, diarrhea, abdominal bloating, abdominal discomfort, and 
excessive flatulence (Gibson, 2017). The term “FODMAP” was developed by researchers 
at Monash University in Melbourne, Australia in 2004 (Gibson, 2017). The low 
FODMAP diet focuses on the elimination or limitation of many foods that are considered 
to contain high amounts of FODMAPs (Mitchell, Porter, Gibson, Barrett, & Garg, 2018). 
When this diet is initiated there is typically an elimination period that lasts approximately 
3-8 weeks, then there is a reintroduction phase (Gibson, 2017). The reintroduction phase 
involves reintroducing certain foods one at a time for three days each. It is important that 
the reintroduction phase is conducted correctly so patients can identify specific foods that 
cause GI symptoms for themselves specifically (Gibson, 2017). Examples of foods that 
are limited on this diet include onions, garlic, apples, wheat products, milk, yogurt, soft 




of foods that are suitable for this diet include carrots, celery, red bell pepper, sweet 
potato, blueberries, grapes, strawberries, hard cheeses, gluten-free products, lactose-free 
milk, and white potatoes (Mitchell, Porter, Gibson, Barrett, & Garg, 2018).  
Eswaran, Chey, Han-Markley, Ball, and Jackson (2016) compared the effects of a 
low FODMAP diet versus a diet modified from the National Institute for Health and Care 
Excellence (mNICE) in patients with IBS-D. The diet modified from the mNICE 
guidelines included eating smaller meals more frequently, limiting caffeine and alcohol, 
and avoiding foods that are known to cause symptoms (Eswaran, Chey, Han-Markley, 
Ball, and Jackson, 2016). Approximately 52% of the participants in the low FODMAP 
diet group reported significant relief of their IBS-D symptoms, while 41% of the 
participants in the mNICE group reported significant relief of their IBS-D symptoms. The 
participants in the low FODMAP group also reported greater reductions in their average 
daily scores for abdominal pain, bloating, stool consistency, stool frequency, and urgency 
of bowel movements (Eswaran, Chey, Han-Markley, Ball, & Jackson, 2016). Staudacher, 
Whelan, Irving, and Lomer (2011) investigated the effects of a low FODMAP diet versus 
standard dietary guidelines for patients with IBS. The NICE guidelines were also used in 
this study and were the standard dietary guidelines for patients with IBS at this time. 
Approximately 76% of the patients in the low FODMAP group reported satisfaction with 
their symptom relief, while 54% of the patients in the standard group reported satisfaction 
with their symptom relief (Staudacher, Whelan, Irving, & Lomer, 2011). The patients in 
the low FODMAP group also reported significant improvements in abdominal pain (low 
FODMAP 85% versus standard 61%), bloating (low FODMAP 82% versus standard 




 Despite the favorable results seen in many studies evaluating the efficacy of a low 
FODMAP diet there are concerns about the restrictiveness of the diet (Hill, Muir, & 
Gibson, 2017). There is concern that the low FODMAP diet may lead to a risk of 
inadequate intake of important nutrients and disordered eating patterns. There is also 
concern that long-term strict restriction of high FODMAP foods may induce a potentially 
unfavorable gut microbiota (a decrease in beneficial bacteria) due to the prebiotic actions 
found in fructans and galacto-oligosaccharides. (Hill, Muir, & Gibson, 2017). O’Keefe et 
al. (2017), evaluated the long-term effects of the low FODMAP diet on GI symptoms, 
food intake, patient acceptability of the diet, and healthcare utilization in IBS patients. 
Approximately 12% of participants reported satisfactory relief of symptoms at baseline, 
61% at the short-term follow up appointment, and 57% at the long-term follow up 
appointment. At the long-term follow up appointment 82% of the participants continued 
to follow a low FODMAP diet that was adapted to their individual trigger foods. The low 
FODMAP group reported that the diet costed appreciably more than their typical diet and 
affected social eating habits (O’Keefe et al., 2017).    
Alternative Treatments 
 Recent studies have found that 50% of IBS patients utilize complementary and 
alternative medicine (CAM) as treatment for their IBS symptoms (Hussain & Quigley, 
2006; Kong et al., 2005). Herbal therapies, probiotics, turmeric, artichoke leaf extract, 
hypnotherapy, cognitive-behavioral therapy, relaxation techniques, acupuncture, and 
exercise have all been studied for their potential positive effects on IBS symptoms (Chey, 
Maneerattaporn, & Saad, 2011; Yoon, Grundmann, Koepp, & Farnell, 2011).  Mind-body 




exercise are the most common CAM therapies that are sought out by IBS patients (Yoon, 
Grundman, Koepp, & Farnell, 2011). Mind-body therapies may potentially have a 
positive impact on the quality of life for IBS patients because many IBS patients have 
fears and anxiety related to their GI symptoms (Lackner, Gudleski, Ma, Dewanwala, & 
Naliboff, 2014). Many types of psychotherapy have been studied in IBS patients 
including cognitive-behavioral therapy, gut-directed hypnotherapy, psychodynamic 
psychotherapy, and mindfulness (Kinsinger, 2017). Cognitive-behavioral therapy has 
been the focus and has been tested in at least 20 published randomized controlled trials 
which conclude that cognitive-behavioral therapy is an effective way to improve IBS 
symptoms (Laird et al., 2016).  
 Probiotics are beneficial bacteria that are found naturally in the body, which have 
been studied in the treatment of IBS symptoms in patients (Roblin et al., 2009). 
Probiotics are defined as live, micro-organisms that can cause a health effect on the host 
when consumed in adequate amounts (Butel, 2014). Lactobacillus, Bifidobacterium, 
enterococcus, streptococcus, and leuconostoc are the most common strains of probiotics 
that are available commercially (Peyton & Greene, 2014).  There are five criteria that 
must be met in order for a probiotic to be considered effective: 1) it must not be toxic or 
pathogenic; 2) it must produce a beneficial effect on the host; 3) it must contain a large 
number of viable micro-organisms per pill; 4) it must be able to survive the intestine, 
reproduce, maintain itself, and have intraluminal metabolic activity; and 5) it must stay 
viable while being stored and used (Dai, Zheng, Jiang, Ma, & Jiang, 2013). Probiotics 
have various actions and may improve IBS symptoms by decreasing bacterial overgrowth 




cytokines and the anti-inflammatory cytokines (Peyton & Greene, 2014). Probiotics may 
also inhibit pathogen binding in the intestinal cells, enhance mucosal barrier function, 
effect colonic transit and motility, have an anti-inflammatory effect, reduce intestinal 
permeability and bacterial translocation, and function in metabolic reactions (Dai, Zheng, 
Jiang, Ma, & Jiang, 2013). The Treatment section of the IBS Clinical Practice Guidelines 
concluded that probiotics have the potential to improve multiple IBS symptoms and 
generally have been found to be effective in treating IBS patients (Whelan & Quigley, 
2013). 
 A systemic review of randomized controlled trials investigating the use of 
exercise therapy in IBS patients which found that quality of life, anxiety, GI symptoms, 
and IBS-related comorbidities showed more significant symptom improvements with 
exercise therapy when compared to typical lifestyle maintenance (Zhou, Zhao, Li, Jia, & 
Li, 2018). Very few studies showed that exercise is as effective as medications or a low 
FODMAP diet for the treatment of IBS symptoms (Zhou, Zhao, Li, Jia, & Li, 2018). El-
Sahey, Lillebo, Reinemo, Salmelid, and Hausken (2010), conducted a study evaluating 
the effects of a health program including patient education, diet management, probiotics, 
and exercise on the symptoms and quality of life of IBS patients and found that 
symptoms scores and quality of life scores were significantly improved at the completion 
of the program. Zhao, Ni, Zhang, and Tian (2019) conducted a similar study evaluating 
the effects of cognitive behavioral therapy combined with exercise on IBS-D patients. 
They found that a combination of cognitive behavioral therapy and exercise can have a 
positive impact on IBS patients (Zhao, Ni, Zhang, & Tian, 2019). These researchers 




combination of treatments/therapies may need to be used (El-Sahey, Liilebo, Reinemo, 














 The purpose of this study was to compare the quality of life scores for each 
specific type of IBS (IBS-D, IBS-C, and IBS-M). This study used an online survey 
design that included the validated Irritable Bowel Syndrome Quality of Life 
Questionnaire (IBS-QOL) (Rome Foundation, 2012). The IBS-QOL questionnaire was 
developed by the Rome Foundation who also developed the Rome IV IBS diagnostic 
criteria. The Rome Foundation works to develop and legitimize the diagnosis and 
treatment of disorders of gut brain interactions (DGBIs). The IBS-QOL questionnaire has 
been validated in several countries and is used to assess the impact of IBS and its 
treatment on quality of life. This survey is available in English as well as many other 
languages including French, Spanish, Italian, German, etc. The IBS-QOL questionnaire 
assesses quality of life in IBS patients using a total scale score and eight subscales 
including: body image, dysphoria, interference with activities, healthy worry, food 
avoidance, social reactions, sexual health, and effect on relationships. The author’s 
scoring formulas that were used for calculations are included in Appendix B. The 
questionnaire was included in an online survey developed on Qualtricsᵀᴹ software and 
was distributed through a link provided on various social media outlets including 
Facebook, IBS Support Groups on Facebook, and Instagram. The groups chosen included 




trained dietitians were also contacted and asked to share the survey with their patients. 
Demographic data including gender, age, household income, education level, health 
insurance status, country of residence, and race was also collected. 
 Institutional Review Board (IRB) approval was obtained from the Louisiana Tech 
University Human Use Committee.  
Sample 
 Eligible participants for this study included persons who have been diagnosed by 
a physician to have IBS, are 18 years of age or older, and reside in the United States. 
Potential participants were excluded if they could not read and speak English (the survey 
was only provided in English), completed less than 50% of the survey, have not been 
diagnosed with IBS by a physician or if they have been diagnosed with additional 
gastrointestinal diseases (with similar symptoms) such as Crohn’s Disease, Celiac 
Disease, or Ulcerative Colitis. The target sample size was 250 participants. Subjects were 
recruited via personal accounts on social media and the survey was posted in several 
large public IBS Support Groups that are present on Facebook. Approximately 130 
FODMAP diet trained dietitians were also contacted and asked to share the survey with 
their patients.  
Data Collection Instruments 
 Data collection was conducted via an online questionnaire using the Qualtrics 
software. The Irritable Bowel Syndrome Quality of Life Questionnaire (IBS-QOL) was 
included. A licensure agreement was provided by the Rome Foundation who developed 




QOL Questionnaire for this study. The IBS-QOL questionnaire includes a total of 34 
items which assess quality of life of IBS patients and includes eight subscales: body 
image or dysphoria, interference with activities, health worry, food avoidance, social 
reactions, sexual health, and effect on relationships. Eight items assess dysphoria, 7 items 
assess interference with activities, 4 items assess body image, 3 items assess food 
avoidance, 4 items assess social reactions, 2 items assess sexual health, 3 items assess 
effects on relationships, and 3 items assess health worry. The scores for the subscales 
could range from 0-100, while the total quality of life scores could be over 100. 
Demographic information included gender, age, household income, education level, 
health insurance status, country of residence, how much spent monthly on IBS, and race. 
The link to the questionnaire was posted on the researcher’s personal Facebook page, 
Instagram account, the Phi Mu National Connection Facebook group, and was shared to 
public IBS support groups on Facebook. Many of the participants were recruited from the 
public IBS support groups on Facebook. FODMAP diet trained dietitians were also 
contacted and asked to share the survey with their patients.  
Data Collection Process 
 Institutional Review Board (IRB) approval was obtained from the Louisiana Tech 
University Human Use Committee. An introduction social media post describing the 
study (Appendix C) and a link that directs participants to the survey on the Qualtrics 
website was shared on social media outlets including the researcher’s personal Facebook 
page, Instagram account, the Phi Mu National Connection Facebook group, and to the 
public IBS Support (Official) group on Facebook which currently has 72,300 members. 




their patients. Participants were able to provide consent for participation in the study by 
voluntarily completing the survey. The survey was open for approximately 9 weeks. Over 
the course of the 9 weeks several follow up posts were made on the researcher’s personal 
Facebook page and the IBS Support Groups on Facebook to recruit more participants. 
After the survey was closed a technical error was found. It appeared that respondents 
were able to select multiple responses to the 34 statements included in the IBS Quality of 
Life Survey question matrix, which affected the ability to calculate quality of life scores 
and subscale scores for those responses. In the cases where multiple responses were 
selected the ones within 1 point of each other were averaged and those more than 1 point 
apart were designated as a missing value. As an incentive, all participants were provided 
the option to enter a drawing to win a $25.00 Amazon gift card by providing their email 
or phone number on a separate survey that was not linked to their responses.  
Data Analysis 
The Scientific Package for Social Sciences (SPSS) BASE for Students was used 
for statistical analysis (SPSS Statistics for Windows, Version 26.0., 2017). Descriptive 
statistics for participants included age, race, and gender and were reported as frequencies 
and were correlated with the quality of life scale and subscales. Hypotheses one and three 
were tested using analysis of variance (ANOVA) test, hypothesis two was tested using a 
t-test. A p-value of 0.05 (x ± SD; p < .05) was used to define statistical significance. 







CHAPTER 4  
RESULTS   
 
Of the 293 responses to the survey, 192 responses were used for analysis. A total 
of 39 responses were excluded for not meeting study criteria. An additional 54 responses 
were excluded because the respondents have been diagnosed with another gastrointestinal 
disorder; and 14 responses were excluded because they had not been diagnosed with IBS 
by a physician. A total of 107 responses were excluded. There were 87 participants who 
were diagnosed with IBS-D, 36 with IBS-C, 63 with IBS-M, and six were not sure which 
type of IBS they have been diagnosed with.  
Respondent Demographics 
 The majority of respondents were white, non-Hispanic (87.5%); female (92.2%); 
between the ages of 18-35 (78.1%); and had completed a of college degree (75.6%) 
(Table 4-1). Of the total population, approximately 51.1% of respondents were between 
the ages of 18-25, 27.9% of respondents were between the ages of 26-35, 8.9% of 
respondents were between the ages of 36-45, 4.7% of respondents were between the ages 
of 46-55, and 7.4% were 56 or older. Since there were so few males that responded to the 





Demographics of Study Participants (N=192) 
Gender      
 Male 6 (9.5%) 3 (8.3%) 5 (5.7%) 14 (7.3%) 
 Female 57 (90.5%) 33 (91.7%) 81 (93.1%) 177 (92.2%) 
 Prefer Not to Answer 0 (0%) 0 (0%) 1 (1.1%) 1 (0.5%) 
Race      
 White, Non-Hispanic 54 (85.7%) 32 (88.9%) 76 (87.4%) 168 (90.3%) 
 White, Hispanic Origin 32 (3.2%) 4 (11.1%) 11 (12.6%) 17 (9.1%) 
 Other 7 (11.1%) 0 (0%) 0 (0%) 7 (3.8%) 
Age      
 18-25 27 (43.5%) 23 (63.9%) 43 (50%) 97 (51.1%) 
 26-35 21 (33.9%) 4 (11.1%) 27 (31.4%) 53 (27.9%) 
 36-45 7 (11.3%) 4 (11.1%) 5 (5.8%) 17 (8.9%) 
 46-55 0 (0%) 3 (8.3%) 6 (7%) 9 (4.7%) 
 56+ 7 (11.3%) 2 (5.6%) 5 (5.8%) 14 (7.4%) 
Education      
 Some High School, no 
Diploma 
0 (0%) 1 (2.9%) 0 (0%) 1 (0.06%) 
 High School Graduate or 
GED 
5 (8.2%) 1 (2.9%) 5 (6.3%) 12 (6.7%) 
 Trade/Technical/Vocational 
Training 
2 (3.3%) 0 (0%) 3 (3.8%) 5 (2.8%) 
 Some College Credit, no 
Degree 
13 (21.3%) 3 (8.8%) 10 (12.7%) 27 (15.2%) 
 Associate Degree 4 (6.6%) 4 (11.8%) 5 (6.3%) 13 (7.3%) 
 Bachelor’s Degrees 23 (37.7%) 14 (41.2%) 36 (45.6%) 76 (42.7%) 
 Master’s Degree 11 (18.0%) 11 (32.4%) 15 (18.9%) 38 (21.3%) 
 Professional Degree (MD, 
DDS, PharmD, PhD, DCN) 
 
3 (4.9%) 0 (0%) 5 (6.3%) 6 (3.4%) 








Type of IBS    IBS-M  IBS-C  IBS-D  Total 





Demographics of Study Participants, Females Only (N=178) 
Race      
 White, Non-Hispanic 70 (86.4%) 30 (90.9%) 48 (84.2%) 155 
(87.6%) 
 White, Hispanic Origin 11 (13.6%) 3 (9.1%) 2 (3.5%) 16 (9.1%) 
 Other 0 (0%) 0 (0%) 7 (12.3%) 7 (3.3%) 
Age      
 18-25 39 (48.1%) 22 (66.7%) 26 (46.4%) 87 (51.2%) 
 26-35 26 (32.9%) 3 (9.1%) 19 (33.9%) 48 (28.2%) 
 36-45 5 (6.2%) 4 (12.1%) 7 (12.5%) 16 (9.4%) 
 46-55 6 (7.4%) 3 (9.1%) 0 (0%) 9 (5.3%) 
 56+ 5 (6.2%) 1 (3%) 4 (7.1%) 10 (5.9%) 
Education      
 Some High School, no 
Diploma 
0 (0%) 1 (3.2%) 0 (0%) 1 (0.06%) 
 High School Graduate or 
GED 
5 (6.8%) 0 (0%) 5 (9.1%) 10 (6.3%) 
 Trade/Technical/Vocational 
Training 
2 (2.7%) 0 (0%) 2 (3.6%) 4 (2.5%) 
 Some College Credit, no 
Degree 
8 (11%) 3 (9.7%) 11 (20%) 22 (13.8%) 
 Associate Degree 4 (5.5%) 3 (9.7%) 4 (7.3%) 11 (6.9%) 
 Bachelor’s Degrees 35 (47.9%) 13 (41.9%) 20 (36.4%) 68 (42.5%) 
 Master’s Degree 15 (20.5%) 11 (35.5%) 11 (20%) 37 (23.1%) 
 Professional Degree (MD, 
DDS, PharmD, PhD, DCN) 
 
5 (6.8%) 0 (0%) 2 (3.6%) 7 (4.4%) 
Note. Some of the total numbers do not add up to 178 due to missing responses to survey questions. 
 
Total Quality of Life Scores 
 Valid t-tests could not be run as too few males responded to the survey. Data 
comparing the total quality of life scores among races, types of IBS, education levels, and 
monthly spending on IBS were analyzed using an ANOVA (Tables 4-3 & 4-4). There 
were no significant differences found between total quality of life scores between patients 
Variable    IBS-M  IBS-C  IBS-D  Total 




with genders, races, types of IBS, and education levels (Table 4-3). A significant 
difference was found between the different groups based on how much money 
participants spend monthly on treatments for/managing their IBS symptoms (F(4, 149)= 
10.81, p= 0.000) (Table 4-3). As spending increased, the total IBS-QOL score decreased. 
Data examining the effectiveness of Registered Dietitians in IBS patients was analyzed 
using a t-test. There were no significant differences found between patients who had seen 
a Registered Dietitian compared to patients who had not seen a Registered Dietitian and 



































ANOVA Comparing Irritable Bowel Syndrome Quality of Life Scores between , Races, 
Types of IBS, Education Levels, and Monthly Spending Groups (N=164) 
Race    1.28* 0.28 
 White, Non-Hispanic 146 56.21 ± 21.89   
 White, Hispanic Origin 14 47.40 ± 21.74   
 Other 4 47.98 ± 10.85   
Type of IBS    0.76* 0.52 
 IBS-M 68 53.41 ± 23.67   
 IBS-C 32 58.72 ± 20.12   
 IBS-D 58 54.63 ± 20.38   
Education    1.84* 0.08 
 Some High School, no 
Diploma 
1 75.00   
 High School Graduate or 
GED 
11 37.37 ± 29.93   
 Trade/Technical/Vocation
al Training 
4 45.49 ± 26.03   
 Some College Credit, no 
Degree 
23 55.23 ± 20.42   
 Associate Degree 12 61.27 ± 23.79   
 Bachelor’s Degrees 65 56.87 ± 20.32   
 Master’s Degree 31 60.92 ± 16.64   
 Professional Degree (MD, 
DDS, PharmD, PhD, 
DCN) 
7 54.83 ± 27.43   
Amount Spent 
Monthly on IBS 
   10.81* <0.0 
 
 $0-20 77 65.78 ± 18.50*   
 $21-50 44 50.51 ± 20.91*   
 $51-75 17 43.29 ± 16.39*   
 $76-100 9 43.09 ± 20.45*   
 Over $100 7 34.35 ± 21.94*   
 
Note. Some of the total numbers do not add up to 164 due to missing responses to survey questions. One 
Participant selected “Prefer not to answer” for gender. Six participants answered “Not Sure” when asked 
what type of IBS. Seventeen participants did not answer the question regarding education level. Thirty-





Variable  Number of          Total IBS QOL Score       F p-value    






ANOVA Comparing Irritable Bowel Syndrome Quality of Life Scores between Races, 
Types of IBS, Education Levels, and Monthly Spending Groups; Females Only (N=153) 
Race    1.15* 0.32 
 White, Non-Hispanic 135 55.92 ± 22.27   
 White, Hispanic Origin 14 47.40 ± 21.74   
 Other 4 47.98 ± 21.77   
Type of IBS    1.05* 0.37 
 IBS-M 63 52.29 ± 23.87   
 IBS-C 31 59.33 ± 20.15   
 IBS-D 53 54.48 ± 20.86   
Education    1.88* 0.077 
 Some High School, no 
Diploma 
1 75.00   
 High School Graduate or 
GED 
11 37.37 ± 29.93   
 Trade/Technical/Vocatio
nal Training 
3 43.87 ± 31.63   
 Some College Credit, no 
Degree 
20 53.69 ± 20.35   
 Associate Degree 10 61.39 ± 24.38   
 Bachelor’s Degrees 62 57.14 ± 220.69   
 Master’s Degree 31 60.92 ± 16.64   
 Professional Degree 
(MD, DDS, PharmD, 
PhD, DCN) 
6 50.37 ± 27.12   
Amount Spent 
Monthly on IBS 
   10.69* <0.01 
 $0-20 75 65.49 ± 18.65*   
 $21-50 40 48.70 ± 20.29*   
 $51-75 15 42.67 ± 17.39*   
 $76-100 7 42.65 ± 23.41*   
 Over $100 7 34. 35± 21.94*   




Variable    Number of      Total IBS QOL Score    F          p-value    






T-Test Examining the Effect of Registered Dietitian on Quality of Life Scores in Patients 




   0.49* 0.48 
 Have Seen 31 51.03 ± 20.53   
 Have Not Seen 125 56.19 ± 22.35   




   0.21 0.65 
 Beneficial 18 57.31 ± 19.60   
 Not Beneficial 10 43.24 ± 20.13   
Note. Effectiveness of Registered Dietitian is a small population since only 31 respondents had seen a 
Registered Dietitian.  
 
 
Quality of Life Subscale Scores 
 There were too few males to run statistics to analyze the differences in quality of 
life subscale scores between males and females.  
The IBS quality of life subscale scores between patients with IBS-M, IBS-C, and 
IBS-D were analyzed using an ANOVA (Tables 4-6 & 4-7). Patients with IBS-M, IBS-C, 
and IBS-D were found to have a significant difference between their subscale scores for 
the interference with activities subscale (F (3, 178)= 5.83, p= 0.001). Significant 
differences between IBS-M, IBS-C, and IBS-D patients were also found in the body 
image (F (3,185)= 3.61, p=0.014) and healthy worry (F (3, 183)= 4.83, p= 0.003) 
subscales (Table 4-6). The results shown in (Table 4-6 & 4-7) reflect a negative impact of 
Variable    Number of      Total IBS QOL Score    F          p-value    





IBS on quality of life to varying degrees in each of the subscales for IBS-M, IBS-C, and 
IBS-D.  
The IBS quality of life subscale scores among races were analyzed using  
ANOVA (Tables 4-8 & 4-9). Significant differences between three subscale scores were 
found among white, non-Hispanic; whites, Hispanic origin; and others (native 
Americans, Asian/Pacific Islanders, Multi-racial, and Asian Indians). The three subscales 
were dysphoria (F (2, 181)= 3.86, p=0.02, social reaction (F (2, 182)=3.23, p= 0.04), and 
relationships (F(2, 184)= 3.58, p= 0.030) (Table 4-8).  
Table 4-6 
ANOVA Comparing Irritable Bowel Syndrome Quality of Life Subscale Scores between 
IBS-M, IBS-C, and IBS-D of the Total Population (N=181) 
Dysphoria 56.71 ± 27.12 55.06 ± 27.75 61.07 ± 24.90 55.01 ± 30.61 1.05* 0.37 
Interference 
with Activities 




56.98 ± 24.77 
 
55.63 ± 25.86 
 
47.74 ± 25.54 
 








55.10 ± 23.05 
 
53.01 ± 24.91 
 
45.83 ± 22.07 
 









34.48 ± 28.00 
 
34.51 ± 31.03 
 
40.60 ± 24.93 
 









54.32 ± 26.05 
 
53.04 ± 27.03 
 
59.82 ± 24.49 
 








65.26 ± 30.80 
 
64.16 ± 31.89 
 
60.59 ± 33.70 
 








68.18 ± 25.12 
 
68.60 ± 25.43 
 
69.56 ± 26.76 
 






Note. Six participants answered “Not Sure” when asked what type of IBS diagnosis.  
*Significant at p <0.05 
 
 
IBS QOL    Total        IBS-M      IBS-C        IBS-D        F        p-value 
Subscale   n= 181         n=63         n=31                 n=87                   





ANOVA Comparing Irritable Bowel Syndrome Quality of Life Subscale Scores between 
IBS-M, IBS-C, and IBS-D of Females Only (N=152) 
Dysphoria 56.85 ± 27.66 54.52 ± 28.19 62.78 ± 24.46 54.98 ± 28.15 1.30* 0.27 
Interference 
with Activities 




56.11 ± 24.84 
 
54.38 ± 25.61 
 
48.48 ± 26.56 
 








54.70 ± 22.79 
 
52.54 ± 24.29 
 
46.21 ± 22.95 
 









34.24 ± 28.29 
 
33.54 ± 31.04 
 
40.28 ± 25.47 
 









54.00 ± 26.15 
 
52.10 ± 27.18 
 
61.91 ± 24.24 
 








65.43 ± 30.89 
 
63.80 ± 31.52 
 
62.31 ± 34.53 
 








68.75 ± 25.04 
 
69.12 ± 24.84 
 
61.97 ± 26.34 
 






Note. Six participants answered “Not Sure” when asked what type of IBS diagnosis.  














IBS QOL    Total  IBS-M            IBS-C           IBS-D          F         p-value 
Subscale   n= 152              n=63              n=36              n=53                   





ANOVA Comparing Irritable Bowel Syndrome Quality of Life Subscale Scores between 
Whites, Non-Hispanic, Whites, Hispanic, and Others of the Total Population (N=192) 








56.98 ± 24.77 
 
57.27 ± 24.57 
 
47.79 ± 24.99 
 








55.10 ± 23.05 
 
55.38 ± 23.75 
 
50.00 ± 17.48 
 









34.48 ± 28.00 
 
35.66 ± 27.73 
 
27.45 ± 31.7 
 









54.32 ± 26.05 
 
56.13 ± 25.72 
 
41.91 ± 24.88 
 








65.26 ± 30.80 
 
65.59 ± 30.96 
 
58.82 ± 31.80 
 








68.18 ± 25.12 
 
69.94 ± 24.79 
 
57.60 ± 26.20 
 






Note. The other category included Native American, Asian/Pacific Islander, Multi-Racial, Asian Indian, 
and other.  










IBS QOL    Total  White, Non-      White,         Other           F            p-value 
Score      Hispanic        Hispanic        
    n= 192     n=168    n=17           n=7                   





ANOVA Comparing Irritable Bowel Syndrome Quality of Life Subscale Scores between 
Whites, Non-Hispanic, Whites, Hispanic, and Others of Females Only (N=153) 
Dysphoria 56.85 ± 27.66 59.09 ± 26.87 44.24 ± 30.67 38.39 ±26.19* 3.838 0.02 
Interference 
with Activities 




56.11 ± 24.84 
 
56.21 ± 24.58 
 
48.05 ± 25.79 
 








54.70 ± 22.79 
 
54.80 ± 23.53 
 
51.11 ± 17.50 
 









34.24 ± 28.29 
 
35.64 ± 28.02 
 
25.52 ± 31.7 
 










53.99 ± 26.15 
 
55.93 ± 25.73 
 










65.43 ± 30.89 
 
65.71 ± 30.99 
 
59.38 ± 32.76 
 








68.75 ± 25.04 
 
70.72 ± 24.53 
 








Note. The other category included Native American, Asian/Pacific Islander, Multi-Racial, Asian Indian, 
and other.  
*Significant at p < .05 
IBS QOL    Total     White, Non-          White,             Other           F          p-value 
Score          Hispanic       Hispanic        
    n= 153         n=135        n=14        n=4                   










This study examined the potential differences in quality of life scores between 
patients with IBS-M, IBS-C, and IBS-D. Approximately half of respondents to this 
survey suffer from IBS-D, while the smallest number suffer from IBS-C.  Other studies 
have found that the percentage of IBS suffers who have each type varies widely, but it is 
estimated that approximately 1/3 of IBS participants suffer from IBS-M, 1/3 suffer from 
IBS-C, and 1/3 suffer from IBS-D (Corsetti & Whorwell, 2017; Nellesen, et al., 2013; 
Singh et al., 2015). 
 A large majority of the respondents to this survey were female. These findings 
align with many other studies which have found that more females suffer from IBS than 
males (Anbardan et al.; Kosako, Akiho, Miwa, Kanazawa, & Fukudo, 2018; Ladabaum et 
al., 2011; 2012 Lovell & Ford, 2012; Pan, Chang, Su, & Tsai, 2016). The higher 
occurrence of IBS diagnosis in females may be associated with stress levels and 
emotional distress. According to the American Psychological Association (2012) women 
report higher stress levels and are more likely than men to report physical and emotional 
symptoms of stress. Psychological and emotional stress are very important factors in the 




Lee et al., 2015; Mykletun et al., 2010; Qin, Cheng, Tang, & Bian, 2014).  Gulewitsch et 
al. (2013), reports that approximately 94% of IBS patients suffer from a psychological 
condition such as generalized anxiety disorder or depression. Additional studies have also 
found that a significant number of IBS patients suffer from psychological disorders and 
emotional stress (Kabra & Nadkarni, 2013; Mykletun et al., 2010). Males had lower 
mean scores in the dysphoria, interference with activities, food avoidance, sexual, and 
relationships subscale categories. Females had lower mean scores in the body image, 
health worry, and social reaction categories.  
Slightly over half of the participants in this study were between the ages of 18-25 
years, while another quarter were between the ages of 26-35 years. These results differ 
from other studies that have found the mean age of IBS diagnosis to be 46 years and that 
the incidence of IBS diagnosis increases with age (Ladabaum et al., 2011; Pan, Chang, Su 
& Tsai, 2016). The increased number of responses in the 18-25 category may be related 
to the way the survey was shared. Because personal social media was used, the education 
levels and ages of the respondents may not be reflective of the general IBS population.  
The survey was also shared to multiple IBS Support groups on Facebook that include 
members of all ages, so these groups likely contributed many of the responses from 
participants over the age of 25 years. The education levels of the respondents also may be 
related to how the respondents were recruited. A large majority of the participants had 
received some type of college degree. Many of the friends on the researcher’s personal 
Facebook page have received a college degree, while all of the members of the sorority’s 




This study found that IBS had a negative impact of the quality of life of 
respondents. While the quality of life subscale scores varied between groups it was 
evident that IBS negatively impacted all patients in each of the eight subscale categories. 
The total IBS quality of life scores and subscale scores had a range of 0-100. Overall, the 
IBS-C group had the highest total quality of life scores (113.86 ± 27.37), only having 
lower subscale scores than the IBS-M or IBS-D groups in three categories (body image, 
health worry, and sexual).  Lower scores in the body image category from patients with 
IBS-C may be related to abdominal distension and bloating which are the predominant 
symptoms of IBS-C (Nellesen, Yee, Chawla, Lewis, & Carson, 2013). Abdominal 
distension and bloating can significantly impact the outward appearance of the abdomen 
which often negatively impacts body image.  IBS-C also may cause abdominal pain, 
nausea, and severe constipation (Nellesen, Yee, Chawla, Lewis, & Carson, 2013). These 
symptoms may contribute to health worry in patients with IBS-C because they may feel 
concerned about the reasons their bowels move slower than normal. Constipation, gas, 
bloating, pain, feelings that the bowels are unable to empty completely, and rectal 
bleeding (which can be attributed to straining due to difficulty during bowel movements) 
are also signs of colon cancer, bowel obstructions, and rectal cancer (Mayo Clinic, 2021). 
These symptoms can be frightening to patients especially if they are severe and chronic in 
nature.  
Registered dietitians can potentially have a significant impact on the quality of 
life for patients with IBS. Many IBS patients attribute some of their GI symptoms to the 
consumption of certain foods. Since registered dietitians are experts in food and nutrition, 




them follow the low FODMAP diet if their symptoms are severe enough. Dietitians can 
become certified in the low FODMAP diet, so these dietitians specifically could be very 
beneficial. The quality of life scores for food avoidance were the lowest for each type of 
IBS showing that food avoidance has a significant impact on quality of life in IBS 
patients.  
The IBS-D group had the lowest scores in the interference with activities, food 
avoidance, social reaction, and relationships subscales, indicating a higher impact of IBS-
D on these subscales. They had the highest scores in the body image, health worry, and 
sexual subscales, indicating a lesser impact of IBS-D on these subscales. Increased bowel 
frequency and diarrhea can affect the abilities of patients to participate in normal daily 
activities such as, work, travel, and exercise (Lacy, 2016). One can assume that impaired 
abilities to participate in daily activities can have negative impacts on relationships and 
social interactions. Patients with IBS often contribute their GI symptoms with diet and 
certain foods. Patients with IBS-D report a lower quality of life related to the burden of 
food avoidance (Singh et al., 2015). The increased food avoidance in patients with IBS-D 
may be related to patient or physician driven diet changes aimed at reducing frequency 
and severity of symptoms. The IBS-M group quality of life subscale scores fell between 
the scores of the IBS-C and IBS-D groups in all categories. This is likely because patients 
with IBS-M experience both constipation and diarrhea, so their perceived quality of life 
may vary based on the symptoms currently being experienced.  
A large majority of the study respondents were white, non-Hispanic (87.5%) 
which may be attributed to where participants were recruited from to complete the 




while Native Americans, Asian/Pacific Islanders, multi-racial, and Asian Indians were 
grouped into the “Other” category which accounted for the last 3.6% of respondents. 
Significant differences were found between Hispanics; White, Non-Hispanics; and the 
other group for the dysphoria, social reaction, and relationships subscales. White, 
Hispanic respondents had higher mean scores than the two other groups in all three of 
these subscales. The lower mean subscale scores for respondents of Hispanic origin in the 
social reaction and relationship categories are interesting because it has been reported that 
people of Hispanic origin often feel obligated to ask for encouragement and advice about 
health issues from many family members (Caballero, 2011). These feelings of obligation 
and loyalty to their family may cause stress or emotional distress because they may feel 
they must consult family members prior to making health-related decisions (Caballero, 
2011).  
Respondents in the “Other” category had the lowest mean scores in the dysphoria, 
interference with activities, food avoidance, social reaction, and relationship subscales. 
The white, non-Hispanic group had the highest scores in the dysphoria, interference with 
activities, body image, food avoidance, social reaction, and relationships subscales. Many 
studies have found significant racial disparities in health care between white, non-
Hispanic people and people of color, so these healthcare disparities may contribute to the 
higher quality of life subscale scores in white, non-Hispanic people (Cook, McGuire, & 
Zaslavsky, 2012; Lau, Lin, & Flores, 2012; Williams & Wyatt, 2015; Derose, Gresenz, & 
Ringel, 2011).  
Monthly spending related to IBS treatment and symptom management also seems 




reported spending $0-50 per month related to their IBS treatments, medications, etc. 
According to the American Psychological Association (2015), money is the leading cause 
of stress for Americans. Stress is likely the reason why total quality of life scores were 
lower in this study for participants who reported spending $51 to over $100 per month on 
IBS related costs. The higher spending related to IBS may also be related to severity of 
symptoms because they may be spending more on medications or treatments to manage 
symptoms, which may also contribute to the lower quality of life scores in this group. 
The total quality of life scores were the highest in the group who reported spending $0-20 
per month, while they were significantly lower in the group who reported spending over 
$100 per month. Emotional and psychological stress are strongly related to the severity 
and development of IBS symptoms, so it is understandable that as financial burden 
increases, stress levels may also increase, which may increase severity of IBS symptoms 
causing reduced quality of life (Jerndal et al., 2010; Lackner et al., 2010 ; Lee et al., 
2015; Mykletun et al., 2010; Qin, Cheng, Tang, & Bian, 2014).   
Education levels of patients with IBS may also contribute to reported quality of 
life. In this study most of the groups with higher education levels reported higher total 
quality of life scores when compared to the groups with lower education levels. One 
exception is the “Some High School, no diploma” category which reported the highest 
total quality of life score out of all the groups, but there was only one respondent in that 
category so overall this may be not be indicative of the quality of life of people in this 
group. The higher quality of life scores in the groups with higher education levels may be 
related to having more money or access to resources and healthcare to help manage IBS 




earn an average of 61% more money than people without a college degree. Often 
employers that require a college degree offer health insurance to their employees (Abel & 
Deitz, 2014). Lack of adequate health insurance can lead to significant levels of 
insecurity for people, so this may also affect quality of life in IBS patients with lower 
education levels.   
There were a few limitations to the current study. All survey responses were self-
reported, so it is possible that some respondents may have contributed inaccurate data. It 
is also possible that respondents accidentally skipped certain questions or selected an 
incorrect answer choice. The use of an electronic survey also may have been geared 
toward the younger or more tech savvy population. Secondly, the survey was initially 
shared primarily on the social media platform of Facebook. While the survey was shared 
to a large number of IBS patients through IBS Support groups present on Facebook it is 
possible that many of the group members have group notifications turned off or do not 
check the group often for new posts. Another limitation of the survey recruitment being 
on social media is that the older IBS population may not have been reached. Late in the 
process of survey sharing many FODMAP diet trained dietitians were contacted and 
asked to share the survey link with their clients. Many of these dietitians agreed and 
shared the link, so it likely would have been very beneficial to utilize this recruitment 
method initially. Additionally, the respondents were primarily white, non-Hispanic and 
between the ages of 18-25 which is not reflective of the general population of IBS 
patients. There were  only 14 male respondents out of the 192 total responses used for 
data analysis, so this limited the statistical analysis of the differences in quality of life 




This study also had several strengths. This study included many demographic 
questions along with the IBS Quality of Life questionnaire (IBS-QOL) questions that are 
not included in many previous studies using the IBS-QOL questionnaire. This study 
compared the quality of life total scores and subscores between all three types of IBS, 
while many studies focus on IBS-D and IBS-M. This study also compared the quality of 
life subscale scores between the different races which to date has not been seen in the 



























CONTENT LICENSE AGREEMENT 
This LICENSE AGREEMENT ("Agreement"), effective as of 21st day of August 
2020 (“Effective Date”), by and between the Rome Foundation, Inc. (“ROME” or 
“Licensor”), an organization with offices at 14460 Falls of Neuse Rd. Ste. 149-116 Raleigh, 
NC 27614, USA and Hailey Hutchison (“Licensee”): 
RECITALS 
WHEREAS, ROME owns or has the right to license certain images, tables, and related ancillary 
materials (“Content”); 
WHEREAS, Licensee uses the Rome IV content in Exhibit A. 
WHEREAS, Licensee desires to license Content from ROME; 
WHEREAS, ROME is willing to provide Licensee with a license, pursuant to the terms and 
conditions of this Agreement; and 
NOW THEREFORE, the parties agree as follows: 
AGREEMENT 
1. Grant of License. 
1.1. Grant. Subject to the terms and conditions of this Agreement, and during the Term 
of this Agreement, ROME grants to Licensee a nonexclusive, non-transferable, nonassignable 
(except for as provided herein) license (“Licensee”) to the Content described 
in Exhibit A. 
ROME acknowledges that the Study may be conducted by Licensee, its affiliates and/or 
their contractors and agrees that the rights granted to Licensee under this Agreement will 
also benefit to such affiliates and contractors only to the extend necessary for the conduct 
of the study. 
ROME acknowledges that Licensee may have to communicate the instrument to ethics 
committees, Institution Review Boards or any regulatory authorities to conduct the Study 
and ROME hereby authorizes such communication. 
Usage. The License shall be limited to the purpose of using the IBS-QOL to study the Quality 
of Life in each type of IBS (IBS-D, IBS-C, IBS-M). I plan to compare the quality of life scores 
(the “Licensee Course”). Usage by Licensee shall further be limited by Licensor’s Right of 
Editorial Control. No deletions, alterations, or changes may be made to the Content without the 
written consent of ROME. 
1.2 . Right of Editorial Control. In the event ROME believes in its sole discretion that 
a particular use of, access by, or display by or of Content by Licensee will have an 
adverse effect on the image or reputation of ROME, Licensee shall modify such 
use, access, or display of the Content to address ROME's concerns. 
1.3 . Reservation of Rights. All other rights with respect to the Content (including any 
reproductions or derivative works thereof), whether now existing or which may 
hereafter come into existence, which are not expressly granted to Licensee herein, 
are reserved in ROME. 
2. Term and Termination. 
Term. The initial term (“Term”) of this Agreement shall cover the duration of 
use specified in Section 1.1 from the Effective Date. There is no term end, as long 
as the usage is specific to that outlined in Section 1.1 (Usage). 
2.1. Renewal. This contract covers the duration of this particular use specified in 
Section 1.1 and ends when this intended use is completed. 
2.2. Termination. Any party may terminate this Agreement: 
2.2.1. if there is a material breach, and such breach is not cured within ten (10) 
days of receipt of notice concerning such breach; or 
2.2.2. for any reason or no reason, in its discretion, by giving to the other party 
sixty (60) days' written notice; or 





2.3. Obligations Upon Termination or Expiration. Upon expiration or termination of 
this Agreement, Licensee shall (i) immediately cease using, accessing, displaying or 
otherwise making available all Content; (ii) within ten (10) days after expiration or 
termination, destroy or render inaccessible Content provided by ROME, in any and all 
forms, along with a written certification that all such materials have been destroyed or 
rendered inaccessible; and (iii) within ten (10) days after termination or expiration, pay to 
ROME all sums then owed and outstanding. Upon termination or expiration of this 
Agreement, all rights granted herein shall automatically revert to ROME without further 
notice. 
3. Fees/Royalties. 
3.1. Flat Fee. In consideration of the License granted in this Agreement, 
Licensee shall pay to ROME a fee of $0.00 USD for this period and upon signature of the 
agreement. 
3.2. Billing and Payment. For faster processing time, a wire is preferred over mailing 
a check. Wire instructions can be found below. If additional invoice needs to be created for the 
Licensee, the Rome Foundation will provide this within 10 (ten) days of this agreement being 
executed and upon validation of the License. Licensee agrees to pay the invoice within 30 days of 
receipt. The payment shall be sent to the Rome Foundation at the wire instructions below, or by 
mail to 14460 Falls of Neuse Rd. Ste. 149-116 Raleigh, NC 27614. The Fees shall be exclusive of 
any sales, use, value added, withholding or similar tax and the Licensee shall be liable for any 
such 
taxes. 
ROME FOUNDATION WIRING INSTRUCTIONS 
BANK NAME: WELLS FARGO BANK, N.A. 
BANK ADDRESS: 
For Domestic (US) wires: 
420 MONTGOMERY 
STREET, SAN FRANCISCO, 
CA 94104 
For International wires: 
525 MARKET STREET, SAN FRANCISCO, CA 94105 
BANK PHONE: 919-881-6435 
INCOMING WIRE ROUTING/ABA: 121000248 
BENEFICIARY: ROME FOUNDATION 
BENEFICIARY ACCOUNT 
NUMBER: 2000057776084 
BENEFICIARY ADDRESS: 14460 Falls of Neuse Rd. Ste. 149-116 Raleigh, NC 27614. 
SWIFT CODE: WFBIUS6S (REQUIRED FOR INTERNATIONAL WIRES) 
4. Proprietary Rights. 
4.1. Ownership. Licensee acknowledges and agrees that the Content is and shall remain 
the exclusive property of ROME. Licensee shall not reproduce, copy, sell, sublicense, 
lease, display, perform, modify, transfer or distribute the ROME Content and any 
derivative works thereof, other than as expressly permitted by this Agreement. 
4.2. Copyright Notice. All Content (including any promotional materials in which the 
Content or ROME Marks appear) shall bear the following copyright notice (or other 
reasonable notices requested by ROME): 
4.2.1. Images: “Copyright (or ©) 2000 Rome Foundation, Inc. All Rights Reserved.” 





4.3. Trademark Usage. Neither party shall use any of the other’s marks, logos or other 
identifiers (“Marks”) in any manner, without the trademark owner’s prior written 
approval. The parties reserve the right to review any proposed use of their 
respective Marks and to require changes in such further use, and the other agrees to 
comply with any such requirements. Each party acknowledges and agrees that: (i) 
it shall not use the other’s Marks in a manner likely to diminish the Marks’ 
commercial value; (ii) it shall not knowingly permit any third party to use the 
other’s Marks unless authorized to do so in writing; (iii) it shall not knowingly use 
or permit the use of any mark, name, or image likely to cause confusion with the 
other’s Marks; (iv) all goodwill associated with use of the Marks shall inure to the 
party owning the Marks; (v) the Marks are and shall remain the sole property of 
their owner; (vi) nothing in this Agreement shall confer in either party any license 
rights or right of ownership in the other’s Marks (and Licensee shall not make any 
representation to that effect), or use the other’s Marks in a manner that suggests 
that such rights are conferred. 
4.4. Breach or Threatened Breach. In the event of a breach or a threatened breach of 
any of the provisions of this Section, Licensee acknowledges that a breach or 
threatened breach shall result in irreparable harm to ROME, and ROME shall be 
entitled to seek a preliminary injunction restraining any such person or entity from 
such breach. Nothing contained herein shall be construed as prohibiting ROME 
from pursuing such other remedies as may be available to ROME for any such 
breach. 
5. Confidential Information. 
5.1. Definition. Each party acknowledges that it may be exposed to certain information 
that is not generally known to the public and that would be considered confidential 
and proprietary by the other party (“Confidential Information”). Confidential 
Information includes, without limitation, all competitively sensitive or secret 
business, marketing and technical information disclosed by one party to another, 
such as proposed products and services, affiliate and customer lists, strategic and 
tactical business planning materials, sales and technical training materials, 
information disclosed in customer conferences, meetings and seminars, materials 
obtained from the password protected portion of any party’s web sites or other web 
sites utilized in connection with this Agreement, source code, development-level 
documentation and similar technical information and the contents of this 
Agreement. In addition, the financial terms of this Agreement shall be 
considered Confidential Information. Confidential Information does not include 
such portions of any disclosed information which: (i) are or become generally 
available to the public other than as a result of a disclosure by a party or any of its 
agents, representatives, affiliates, employees or consultants in violation of its or 
their obligations of confidentiality hereunder; or (ii) become available to a party on 
a non-confidential basis from a source which is not prohibited from disclosing such 
information to that party by a legal, contractual or fiduciary obligation to the other 
party. 
5.2. Confidentiality Obligation. Each party agrees that, with respect to received 
Confidential Information, it (i) shall protect such Confidential Information from 
unauthorized disclosure using the highest commercially reasonable standard of 
care, (ii) shall not disclose such Confidential Information to any third party except 
the party’s lawyers, accountants, underwriters and other professionals, and (iii) 
shall not use such Confidential Information (other than as specifically authorized 
by this Agreement) without the prior written consent of the other party. These 




shorter of five (5) years following the date of termination of this Agreement, or 
until such information becomes publicly known other than by breach of this 
Agreement by any party. Within five (5) calendar days after a party’s request, or 
upon termination of this Agreement, all materials or media containing any 
Confidential Information shall either be returned to the originating party or 
destroyed by the other party, at the originating party’s sole discretion, and each 
party agrees to certify its compliance with such obligation upon the request of the 
other party. 
5.3. Compelled Disclosure. In the event that a party or anyone to whom that party 
transmits Confidential Information pursuant to this Agreement becomes legally 
compelled to disclose any of the Confidential Information (“Compelled Party”), 
the Compelled Party will provide the other party (“Furnishing Party”) with 
prompt notice thereof so that the Furnishing Party may seek a protective order or 
other appropriate remedy or waive compliance with the provisions of this 
Agreement. In the event that such protective order or other remedy is not obtained 
by the Furnishing Party or the Furnishing Party waives compliance with the 
provisions of this Agreement, the Compelled Party will furnish or cause to be 
furnished only that minimum portion of the Confidential Information which the 
Compelled Party is legally required to furnish and will exercise commercially 
reasonable efforts to obtain reliable assurances that confidential treatment is 
accorded the Confidential Information so furnished. 
6. Representations and Warranties. 
6.1. ROME warrants and represents that it has the right and authority to enter into this 
Agreement and to grant the rights in the Content set forth herein, subject to the 
limitations and exclusions set forth herein; and that the Content does not and shall 
not infringe upon the rights or interests of any third party. 
6.2. Licensee represents and warrants that it has the power and authority to enter into 
this Agreement and to perform its obligations and, upon execution and delivery 
hereof, this Agreement shall constitute the valid and binding obligations of 
Licensee enforceable in accordance with its terms. 
6.3. CONTENT IS PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND. 
LICENSEE EXPRESSLY AGREES THAT ITS RECEIPT AND USE OF THE 
CONTENT IS AT LICENSEE’S SOLE RISK, AND THAT THE ENTIRE RISK 
AS TO SATISFACTORY QUALITY, PERFORMANCE, ACCURACY AND 
EFFORT IS WITH LICENSEE. LICENSOR HEREBY DISCLAIMS ALL 
WARRANTIES, WHETHER EXPRESS, IMPLIED OR STATUTORY, WITH 
RESPECT TO THE CONTENT. LICENSOR SPECIFICALLY DISCLAIMS THE 
IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A 
PARTICULAR PURPOSE, ACCURACY, AND THOSE ARISING FROM A 
COURSE OF DEALING OR USAGE OF TRADE. 
7. Indemnification. 
7.1. By ROME. ROME shall defend, indemnify and hold harmless Licensee from and 
against any claims, actions or demands, alleging or resulting from the breach of any 
of ROME’s obligations, covenants, representations or warranties under this 
Agreement. 
7.2. By Licensee. Licensee shall defend, indemnify and hold harmless ROME, its 
officers, employees, shareholders, directors, managers, members and suppliers, and 
those of its affiliates including parent companies and subsidiaries, from and against 
(i) any damages or liability of any kind arising from any use of Content other than 
the uses expressly permitted by this Agreement, and (ii) any claims, actions or 




covenants, representations, or warranties under this Agreement. 
8. Limitation of Liability. 
8.1. Limitation of Liability. Other than the indemnification obligation set forth herein, 
ROME shall have no liability or responsibility for claims or actions caused by or 
arising from use, access, or display of the Content not in accordance with this 
Agreement, that arise out of Licensee equipment malfunction or negligence, or that 
arise from the use, access or display of the Content in conjunction with products, 
platforms, or materials not provided by Licensee in accordance with this 
Agreement. NOTWITHSTANDING THE FAILURE OF THE ESSENTIAL 
PURPOSE OF ANY REMEDY, IN NO EVENT WILL ROME BE LIABLE FOR 
ANY INDIRECT, INCIDENTAL, OR CONSEQUENTIAL DAMAGES 
(INCLUDING, WITHOUT LIMITATION, DAMAGES ASSOCIATED WITH 
LOSS OF PROFITS, LOSS OF BUSINESS OPPORTUNITIES OR LOSS OF 
GOODWILL) EVEN IF ADVISED OF THE POSSIBILITY OF SUCH 
DAMAGES, OR FOR ANY MATTER BEYOND ITS REASONABLE 
CONTROL, IN EACH CASE REGARDLESS OF THE FORM OF THE CLAIM 
OR THE THEORY OF RECOVERY. TOTAL CUMULATIVE LIABILITY FOR 
ALL CLAIMS ARISING OUT OF OR RELATED TO ANY SUBJECT MATTER 
OF THIS AGREEMENT, REGARDLESS OF THE FORM OF THE CLAIM OR 
THE THEORY OF RECOVERY, WILL IN NO EVENT EXCEED US$10,000. 
9. PROVISIONS RELATING TO THE FDA REGULATION 
Pursuant to the U.S. regulation called the federal food drug and cosmetics act as amended 
by the generic drug enforcement act of 1992 (GDEA), ROME represents, warrants and 
covenants to Licensee as follows: 
(i) to the best of its knowledge at the time of signing the Agreement neither it nor any 
individual employed or engaged by ROME have ever been and are not currently 
(a) under investigation for debarment or debarred by any relevant health authority 
for debarment action (as detailed in the section 306 of the GDEA of 1992), 
(b) excluded by any relevant agency for debarment action (as detailed in the 
section 306 of the GDEA of 1992), 
(c) otherwise disqualified or restricted by the FDA or any other regulatory 
authority, nor will ROME knowingly utilize any debarred, excluded or 
disqualified personnel to perform services hereunder; 
(ii) it will notify Licensee immediately in writing in the event any investigation or 
proceeding for debarment, exclusion or disqualification is initiated against ROME 
or any employee or personnel during the term of the Agreement or within one (1) 
year following its expiration or termination; 
(iii) its employees or contractors are, and will continue to be, qualified and have, and 
will continue to have, sufficient technical expertise to perform ROME’s obligations 
under this Agreement and will require such for other personnel; if ROME, or any 
of its employees or contractors involved in the services, or any other person or 
organization used by ROME in connection with the services should become 
debarred, disqualified or excluded during the term of this Agreement or within one 
(1) year following its expiration or termination, provider agrees to notify Licensee 
promptly in writing. 
10. MISCELLANEOUS 
10.1 Survival. Sections of this Agreement relating to Confidential Information, 
Indemnification, Limitation of Liability, and Representations and Warranties shall 
survive the expiration or termination of this Agreement. 
10.2 Waiver. Any waiver by either party of its rights under this Agreement shall not 




10.3 Assignment. Licensee shall not assign this Agreement or any of its rights hereunder 
or delegate any of its obligations hereunder except with the prior written consent of 
ROME, except if such assignment is made to the benefice of one of its affiliates. 
10.4 Excusable Delay. If, for any reason beyond its control, either party is unable to 
comply with its responsibilities under this Agreement, then performance by that 
party shall be excused until the reason for such inability ceases to exist. In such 
circumstances, each party shall use its best efforts to comply with the essential 
portions of this Agreement. In the event that such inability shall exist for a period 
of at least thirty (30) days, the parties shall meet to negotiate a resolution of any 
such existing performance problems. If the parties fail to negotiate a resolution 
within thirty (30) days, the Agreement may be terminated at the option of either 
party. 
10.5 Jurisdiction. Any legal action or proceeding concerning the validity, interpretation 
and enforcement of this Agreement, matters arising out of or related to this 
Agreement or its making, performance or breach, or related matters shall be brought 
exclusively in the federal or state courts of the State of North Carolina having 
jurisdiction, and all parties consent to the exclusive jurisdiction of those courts, 
waiving any objection to the propriety or convenience of such venues. The United 
Nations Convention on Contracts for the International Sale of Goods does not apply 
to or otherwise affect this agreement. The validity, interpretation and enforcement 
of this Agreement, matters arising out of or related to its making, performance or 
breach, and related matters shall be governed by the internal laws of the State of 
North Carolina (without reference to choice of law doctrine). Licensee agrees that 
service of process in any actions, controversies, and disputes arising from or 
relating to this Agreement may be effected by mailing a copy thereof by registered 
or certified mail (or any substantially similar form of mail), postage prepaid, to the 
other party however, nothing herein shall affect the right to effect service of process 
in any other manner permitted by law. The invalidity or unenforceability of any 
part of this Agreement shall not affect the validity or enforceability of the balance 
hereof. 
10.6 Illegal Provision. If any covenant or other provision of this Agreement is invalid, 
illegal, or incapable of being enforced by reason of any rule of law, administrative 
order, judicial decision or public policy, all other conditions and provisions of this 
Agreement shall, nevertheless, remain in full force and effect. The parties shall 
make changes to this Agreement as are necessary to cure the invalidity, consistent 
with the original objectives of the parties. 
10.7 No Partnership or Joint Venture. Nothing in this Agreement or the relations 
between the parties to this Agreement shall be construed to constitute a partnership 
or joint venture between or among the parties to this Agreement. Licensee shall 
have no right or authority to bind or obligate ROME in any manner whatsoever and 
shall not expressly or impliedly incur any liability or obligation on behalf of 
ROME. 
10.8. Notices. Any notice or demand required or permitted by this Agreement shall be in 
writing and shall be deemed given when received by the parties at the address set 
forth above. 
10.9. Counterpart Execution. This Agreement may be executed by the parties on any 
number of separate counterparts, and all such counterparts so executed constitute 
one agreement binding on all the parties notwithstanding that all the parties are not 
signatories to the same counterpart. 
10.10. Entire Agreement. This Agreement contains the entire agreement and 




written agreement executed by both of the parties. 
IN WITNESS WHEREOF, each of the parties has caused a duly authorized officer or 
agent to execute this Agreement as of the dates set forth below. 



















DATA COLLECTION INSTRUMENT 
AND 




Quality of Life in Persons with IBS 
 
 
Start of Block: Default Question Block 
 
Q1 The following is a brief summary of the project in which you are asked to 
participate. Please read this information before continuing on to the survey.     
 
PURPOSE OF STUDY/PROJECT: The purpose of this study is to examine the 
differences in the effects of irritable bowel syndrome (IBS) on the quality of life in 
patients with each of the three types of IBS: IBS-Diarrhea (IBS-D), IBS-Constipation 
(IBS-C), and IBS-Mixed (IBS-M).      
 PROCEDURE: You have been directed to this survey by clicking on the link provided 
via a social media post.  The survey will take approximately 10-15 minutes to 
complete.         
RISKS/ALTERNATIVE TREATMENTS: This is a descriptive study therefore there are 
no risks to subjects in the study. As with all online survey tools, the server may collect 
information and your IP address indirectly and automatically via “cookies”.        
BENEFITS/COMPENSATIONS: There are no direct benefits to participating in this 
survey.      I attest by clicking “Yes I am over 18 years of age and agree to participate in 
the study” below that I have read and understood the following description of the study 
“Assessing and Comparing Quality of Life Scores in Patients with Irritable Bowel 
Syndrome-Diarrhea, Irritable Bowel Syndrome-Constipation, and Irritable Bowel 
Syndrome-Mixed”  and its purposes and methods.  I understand that my participation 
and refusal to participate in this study will not affect my relationship with Louisiana Tech 
University. Further, I understand that I may withdraw at any time and refuse to answer 
any questions without penalty. Upon completion of the study, I understand that the 
aggregated results will be freely available to me upon request. I understand that the 
results of the material will be confidential, accessible only to the principal investigators, 
myself or a legally appointed representative. I have not been requested to waive nor do I 
wave any of my rights related to participating in this study.        
 If you have any questions or concerns about completing the survey or being in this 
study you may contact Hailey Hutchison, Graduate Student, at hutchison95@yahoo.com 
or Dr. Vicky Green, faculty advisor, at vgreen@latech.edu.    
Members of the Human Use Committee of Louisiana Tech University may also be 




Director, Office of Intellectual Property & Commercialization Ph: (318) 257-2484, Email: 
rkordal@latech.edu    
o Yes I am over the age of 18 and agree to participate in this survey  (1)  
o I do not agree to participate in the survey  (2)  
 
Skip To: End of Survey If The following is a brief summary of the project in which you are asked 
to participate. Please rea... = I do not agree to participate in the survey 
 
 
Q2 Have you been diagnosed with Irritable Bowel Syndrome (IBS) by a physician? 
o Yes  (1)  
o No  (2)  
 
Skip To: End of Survey If Have you been diagnosed with Irritable Bowel Syndrome (IBS) by a 
physician? = No 
 
 
Q3 Have you been diagnosed with any other Gastrointestinal Disorders such as: Celiac 
disease, Ulcerative Colitis, Crohn's Disease? 
o Yes  (1)  
o No  (2)  
 
Skip To: End of Survey If Have you been diagnosed with any other Gastrointestinal Disorders 






Q4 Do you suffer from IBS-Mixed, IBS-Constipation, or IBS-Diarrhea? 
o IBS-Mixed  (1)  
o IBS-Constipation  (2)  
o IBS-Diarrhea  (3)  
o Other  (4)  




Q5 How long have you been experiencing IBS symptoms? 




Q6 How long have you been diagnosed with Irritable Bowel Syndrome (IBS)? 




Q7 Do you have a family history of Irritable Bowel Syndrome (IBS)? 
o Yes  (1)  
o No  (2)  







Q8 What is your sex? 
o Male  (1)  
o Female  (2)  
o Other  (3)  




Q9 What is your race? 
o White, Non-Hispanic origin  (1)  
o White, Hispanic origin  (2)  
o Black or African American, Non-Hispanic  (3)  
o Black or African American, Hispanic Origin  (4)  
o Native American or Alaskan Native  (5)  
o Asian/Pacific Islander  (6)  
o Asian Indian  (7)  
o Middle Eastern  (8)  
o Multi-racial  (9)  




Q10 What is your age? 







Q11 Do you reside in the United States? 
o Yes  (1)  
o No  (2)  
 
Q12 IBS Quality of Life Survey.  
 
Please think about your life over the past month (30 days), and look at the statements 
below. Each statement has five possible responses. For each statement, please select 
the choice that best describes your feelings.  
 









I feel helpless 
because of 
my bowel 
problems.  (1)  
▢  ▢  ▢  ▢  ▢  
I am 
embarrassed 
of the smell 
caused by my 
bowel 
problems.  (2)  
▢  ▢  ▢  ▢  ▢  
I am bothered 
by how much 
time I spend 
on the toilet.  
(3)  







problems.  (4)  
▢  ▢  ▢  ▢  ▢  
I feel fat 
because of 
my bowel 
problems.  (5)  




I feel like I'm 
losing control 
of my life 
because of 
my bowel 
problems.  (6)  
▢  ▢  ▢  ▢  ▢  




problems.  (7)  
▢  ▢  ▢  ▢  ▢  
I feel 
uncomfortable 
when I talk 
about my 
bowel 
problems.  (8)  





problems.  (9)  
▢  ▢  ▢  ▢  ▢  






▢  ▢  ▢  ▢  ▢  
I have to 
watch the 
amount of 










is difficult for 
me. (12)  
▢  ▢  ▢  ▢  ▢  
I feel angry to 
I have bowel 
problems.  
(13)  










▢  ▢  ▢  ▢  ▢  





▢  ▢  ▢  ▢  ▢  





▢  ▢  ▢  ▢  ▢  
I worry that 





▢  ▢  ▢  ▢  ▢  






▢  ▢  ▢  ▢  ▢  














▢  ▢  ▢  ▢  ▢  
My bowel 
problems limit 
what I can 
wear. (21)  












▢  ▢  ▢  ▢  ▢  
I have to 
watch the 
kind of food I 
eat because 
of my bowel 
problems.  
(23)  






people I do 
not know well. 
(24)  
▢  ▢  ▢  ▢  ▢  





▢  ▢  ▢  ▢  ▢  





▢  ▢  ▢  ▢  ▢  
Long trips are 





▢  ▢  ▢  ▢  ▢  
I feel 
frustrated that 
I cannot eat 
when I want 
because of 
my bowel 










It is important 
to be near a 
toilet because 
of my bowel 
problems. 
(29)  







▢  ▢  ▢  ▢  ▢  
I worry about 
losing control 
of my bowels. 
(31)  
▢  ▢  ▢  ▢  ▢  
I fear I won't 
be able to 
have a bowel 
movement. 
(32)  







▢  ▢  ▢  ▢  ▢  










Q13 Since being diagnosed with IBS have you sought medical intervention? 
o Yes  (1)  
o No  (2)  
 
Skip To: Q15 If Since being diagnosed with IBS have you sought medical intervention? = No 
 
 
Q14 Have medical interventions been helpful or improved your symptoms? 
o Yes  (1)  
o No  (2)  




Q15 Have you been able to identify triggers for your IBS symptoms? (ex. Specific foods, 
stress, anxiety, etc) 
o Yes  (1)  
o No  (2)  
o Unsure  (3)  
 
Skip To: Q17 If Have you been able to identify triggers for your IBS symptoms? (ex. Specific 






Q16 What triggers have you identified? Select all that apply. 
▢ Foods  (1)  
▢ Stress  (2)  
▢ Anxiety  (3)  




Q17 Since being diagnosed with IBS have you made any changes to your diet? 
o Yes  (1)  
o No  (2)  
 
Skip To: Q19 If Since being diagnosed with IBS have you made any changes to your diet? = No 
 
 
Q18 Have these diet changes improved your IBS symptoms? 
o Yes  (1)  
o No  (2)  




Q19 Have you seen a Registered Dietitian or Nutritionist since being diagnosed with 
IBS? 
o Yes  (1)  
o No  (2)  





Skip To: Q22 If Have you seen a Registered Dietitian or Nutritionist since being diagnosed with 
IBS? = No 
Skip To: Q22 If Have you seen a Registered Dietitian or Nutritionist since being diagnosed with 
IBS? = Unsure 
 
 
Q20 What specific diet or diets did the Registered Dietitian or Nutritionist educate you 
about? 
▢ Low FODMAP diet  (1)  
▢ Gluten Free  (2)  




Q21 Did you find your discussion with the Registered Dietitian or Nutritionist beneficial? 
o Yes  (1)  
o No  (2)  




Q22 Do you have health insurance? 
o Yes  (1)  







Q23 How much do you spend out-of-pocket monthly on medications or other treatments 
for IBS? 
o $0-20  (1)  
o $21-50  (2)  
o $51-75  (3)  
o $76-100  (4)  




Q24 What is your total annual household income? 
o Less than $10,000  (1)  
o $10,000 to $19,999  (2)  
o $20,000 to $29,999  (3)  
o $30,000 to $39,999  (4)  
o $40,000 to $49,999  (5)  
o $50,000 to $59,999  (6)  
o $60,000 to $69,999  (7)  
o $70,000 to $79,999  (8)  
o $80,000 to $89,999  (9)  
o $90,000 to $99,999  (10)  
o $100,000 to $149,999  (11)  







Q25 What is the highest degree or level of education you have completed?  
o Less than high school  (1)  
o Some high school, no diploma  (2)  
o High school graduate, diploma or the equivalent (for example: GED)  (3)  
o Trade/technical/vocational training  (4)  
o Some college credit, no degree  (5)  
o Associate degree  (6)  
o Bachelor’s degree  (7)  
o Master’s degree  (8)  
o Doctor of Medicine  (11)  
o Doctor of Dental Science  (12)  
o Doctor of Pharmacy  (13)  
o Doctor of Clinical Nutrition  (14)  
o Other Professional degree  (9)  




Q26 How much do you weigh? Enter in pounds or kilograms.  
 _______ lbs (12) 








Q27 How tall are you? Enter both feet and inches. 
 _______ Feet (1) 
 _______ Inches (2) 








Q29 Do you want to enter a drawing to win a $25 Amazon gift card? 
o Yes  (1)  
o No  (3)  
 
Skip To: Q30 If Do you want to enter a drawing to win a $25 Amazon gift card? = Yes 
 
 



















Transforming and Computing Overall Score and Subscores of IBS-QOL  
  
Summarized by J.B. Hu  
  
  IBS-QOL is a new survey instrument first developed in 1997 to assess health 
related quality of life [QOL] of patients afflicted with irritable bowel syndrome [IBS].  
The instrument was co-developed by Donald L. Patrick, PhD, Douglas A. Drossman, 
MD, and Ihunnaya O. Frederick, in the United States.  This summary is based on the 
User’s Manual for the U.S. version of IBS-QOL authored and published by the three in 
May 1997.  
  
  The original U.S. version of the IBS-QOL contains 34 question items relating to 
symptoms of IBS.  Each item, when answered by the patient, describes the respondent’s 
feelings to a particular symptom.  The magnitude of the respondent’s feelings to each 
item is determined by the patient’s selection of one of the five Likert-style responses 
labeled 1 through 5, where 1=Not at all, 2=Slightly, 3=Moderately, 4=Quite a bit, and 
5=Extremely.  
  
In data analysis, the five responses are transformed in order to obtain a 100-point 
overall score and eight 100-point subscales.   The table below lists names [beginning with 
TOT_] of  the total overall score and 8 subscales, their component items, and acronyms 
[beginning with IBS_]of the final 9 computed 100-point scores:   
  
  Subscale Names and 
Description [total]]  
Sequential order of component items in 
the IBS-QOL  
100-point 
Names  
1  TOT-OV for Overall [34]  All 34 items  IBS_OV  
2  TOT-DY for Dysphoria [8]  IBS01 IBS06 IBS07 IBS09 IBS10 IBS13 
IBS16 IBS30  
IBS_DY  
3  TOT-IN for Interference With 
Activity [7]  
IBS03 IBS18 IBS19 IBS22 IBS27 IBS29 
IBS31  
IBS_IN  
4  TOT-BI for Body Image [4]  IBS05 IBS21 IBS25 IBS26  IBS_BI  
5  TOT-HW for Health Worry [3]  IBS04 IBS15 IBS32  IBS_HW  
6  TOT-FA for Food Avoidance [3]  IBS11 IBS23 IBS28  IBS_FA  
7  TOT-SR for Social Reaction [4]  IBS02 IBS14 IBS17 IBS34  IBS_SR  
8  TOT-SX for Sexual [2]  IBS12 IBS20  IBS_SX  
9  TOT-RL for Relationship [3]  IBS08 IBS24 IBS33  IBS_RL  
  
Step 1 in the transformation is to reverse code the responses, making 5=Not at all, 
4=Slightly, 3=Moderately, 2=Quite a bit, and 1=Extremely.   Manual reverse coding is 
cumbersome, but most statistical analysis packages for personal computers are equipped 
with different ways and shortcuts to the reverse coding.  
  
Step 2 of the transformation calculates a summary total of the overall score and 
eight subscales by totaling up the reverse coded values of the component items in each of 
the 9 groups.  For example, TOT-DY is obtained by adding up all the reverse coded 





  Step 3 computes the final 100-point scores using the following formulas:  
  
  Final 100-point 
Score Names  
Computation Formula  Explanation  
1  IBS_OV   =  ((TOT_OV - 
34)/(136))*100  
  
- denotes subtraction  




Note: No final score should 
exceed 100. Higher scores 
may mean a higher          
quality of life and a less 
degree of IBS symptoms 
and their impact.  
2  IBS_DY   =  ((TOT_DY -  8)/( 
32))*100  
3  IBS_IN   =  ((TOT_IN -  7)/( 
28))*100  
4  IBS_BI   =  ((TOT_BI -  4)/( 
16))*100  
5  IBS_HW   =  ((TOT_HW -  3)/( 
12))*100  
6  IBS_FA   =  ((TOT_FA -  3)/( 
12))*100  
7  IBS_SR   =  ((TOT_SR -  4)/( 
16))*100  
8  IBS_SX   =  ((TOT_SX -  2)/(  
8))*100  
9  IBS_RL   =  ((TOT_RL -  3)/( 
12))*100  
  
  For more details of calculating the scores or to obtain a copy of the original IBS-
QOL questionnaire, the User’s Manual, or other supporting materials, please contact any 
person listed below:  
  
Douglas A. Drossman, MD  
University of North Carolina – Chapel Hill  
CB 7080 BioInformatics Building  
Chapel Hill, North Carolina 27599-7080 USA  
Tel: (919) 966-0141  




Donald L. Patrick, PhD  
Department of Health Services, H689  
Box 357660, University of  Washington  
Seattle, Washington 98195-7660 USA  
Tel: (206) 616-7393  
Fax: (206) 616-3135  
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